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Sensing Inorganic Phosphate Starvation by the Phosphate-Responsive (PHO) 
Signaling Pathway of Saccharomyces cerevisiae 
 
Abstract 
 
 Inorganic phosphate (Pi) is an essential nutrient whose intracellular levels are 
maintained by the PHO pathway in Saccharomyces cerevisiae. Pi limitation triggers 
upregulation of the PHO genes whose gene products primarily function to 
counterbalance the Pi deficiency. Despite a growing catalogue of genes that are 
involved in signaling of the PHO pathway, little is known about how cells actually sense 
Pi limitation.  
 To better characterize the Pi sensing mechanism, I exploited two comprehensive 
and orthogonal approaches: 1) genome-wide genetic screening to identify novel genes 
involved in signaling Pi limitation through the PHO pathway and characterization of 
genetic interactions among these genes and 2) liquid chromatography /mass 
spectrometry (LC/MS)-based metabolic profiling to characterize the metabolomic 
response to changes in Pi availability.  
In genome-wide screening, I found that the aah1 mutant constitutively activated 
the PHO pathway and showed that AAH1 is involved in regulating PHO pathway activity. 
Moreover, I identified several novel genetic interactions of genes involved in inositol  
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polyphosphate metabolism with those involved in purine metabolism and mitochondrial 
fatty acid biosynthesis. 
 Through metabolomic profiling, I showed that all adenine nucleotides were 
downregulated in the constitutively induced ado1, adk1, and aah1 mutants in high Pi as 
well as in the wild type strain in low Pi. These observations led to the hypothesis that 
downregulation of adenine nucleotides triggers activation of the PHO pathway. However, 
I find that decreases in adenine nucleotides appear to be the consequence of 
downregulation of glycolysis and of the pentose phosphate pathway rather than an 
activation signal for the PHO pathway. 
 Among all the detected metabolites, S-adenosyl-L-homocysteine (SAH) 
responded the most quickly and significantly to changes in Pi concentration. It was 
known that SAH is an inhibitor of de novo synthesis of phosphatidylcholine (PC). I 
showed that overall PC levels were downregulated in low Pi, suggesting that 
phospholipid metabolism is downregulated in low Pi conditions. Furthermore, I observed 
that exogenous SAH induces activation of the PHO pathway in high Pi implying a 
possible role of SAH as an initiating activation signal of the PHO pathway. 
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Chapter 1 
Introduction to the Phosphate-responsive Signaling (PHO) Pathway in 
Saccharomyces cerevisiae 
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In order for microorganisms to survive in an unpredictable environment, they 
must monitor changes in environmental conditions and respond to maintain relatively 
constant intracellular conditions for growth. Given that nutrient availability is one of the 
most important environmental factors, cells have developed elaborate networks capable 
of sensing changes in the nutrient availability inside cells or in the environment, 
transferring the signals containing information about the fluctuations, and inducing 
transcriptional response to cope with the changes in nutrient levels. The proper 
regulation of these signaling pathways is essential for fulfilling cellular nutrient needs.  
 
The regulation of the PHO pathway in response to changes in Pi availability 
Inorganic phosphate (Pi) is an essential nutrient required for the synthesis of 
cellular constituents such as phospholipids as components of the plasma membrane 
and synthesis of ATP that is widely used as a carrier of chemical energy in cells. 
Therefore, it is crucial for cells to maintain Pi concentrations in vivo even in low 
extracellular Pi conditions. In Saccharomyces cerevisiae (budding yeast), the 
phosphate-responsive (PHO) signaling pathway is responsible for Pi homeostasis and 
responds to changes in extracellular Pi availability. The first cellular response to a 
decrease in extracellular Pi availability is to increase the uptake rate of Pi from the 
environment by secreting the acid phosphatase Pho5 (Oshima, 1997, To et al., 1973) 
and upregulating transcription of the high-affinity Pi transporter Pho84 (Bun-Ya et al., 
1991). This cellular response is regulated by a core regulator cyclin Pho80 / cyclin-
dependent kinase (CDK) Pho85 / CDK inhibitor Pho81 complex (Figure 1.1.) (Schneider 
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et al., 1994, O'Neill et al., 1996, Kaffman et al., 1994). The Pho80/85 complex 
phosphorylates the transcription factor Pho4 and regulates Pho4 subcellular localization 
depending on the Pi availability. Pho81 is bound to the Pho80/85 complex and required 
for the inhibition of Pho80/85 kinase activity in response to Pi starvation. In Pi limited 
conditions, myo-D-inositol heptakisphosphate (IP7) levels increase and bind to the CDK 
inhibitor Pho81 causing it to inhibit Pho80/85 complex kinase activity (Lee et al., 2007, 
Lee et al., 2008). The loss of Pho80/85 kinase activity allows Pho4 to be 
dephosphorylated (Kaffman et al., 1994), resulting in nuclear  localization (Kaffman et 
al., 1998b). Nuclear Pho4 binds cooperatively with another transcription factor Pho2 to 
PHO promoters (Vogel et al., 1989) and induces transcription of the PHO genes, 
including PHO5 and PHO84. In high extracellular Pi conditions, Pho81’s activity as a 
CDK inhibitor is repressed due to low levels of IP7. This allows Pho4 to be multiply 
phosphorylated by the Pho80/85 complex and excluded from the nucleus (Kaffman et 
al., 1998a). The export of Pho4 from the nucleus turns off transcription induction of the 
PHO regulon.  
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Figure 1. 1. Regulation of the PHO pathway in response to changes in Pi concentration. 
 
Identification of the PHO regulon with microarray analysis 
The advent of genome-wide technologies made it possible to define a 
comprehensive list of genes involved in the PHO regulon. Microarray data comparing 
the expression profiles of cells grown in high and no Pi  conditions identified 22 genes 
regulated by the PHO pathway (Ogawa et al., 2000). In addition to the previously 
identified genes such as PHO5 and PHO84, this study identified eight novel genes 
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PHM1-PHM8 that had no previously defined function in Pi metabolism. Those genes 
were involved in maintaining a pool of polyphosphate, a linear polymer of Pi, within the 
vacuole (Neef and Kladde, 2003) and these stores are mobilized during Pi starvation 
(Thomas and O'Shea, 2005). 
 
Identification of upstream signaling components of the PHO pathway 
While the PHO pathway downstream of Pho80/Pho85/Pho81 had been well 
characterized through biochemical studies and microarray measurements, little was 
known about genes acting upstream of Pho80/Pho85/Pho81. Historically, the high 
affinity Pi transporter Pho84 has been long considered the putative Pi sensor based on 
the constitutive activation of the PHO pathway of the  pho84 mutant and genetic 
evidence that PHO84 acts upstream of the core Pho80/Pho85/Pho81 complex (Bun-Ya 
et al., 1991).  The idea that a nutrient transporter acts as a regulating sensor was 
strengthened by its precedence in other signaling contexts. For example, the plasma 
membrane proteins Snf3 and Rgt2 sense a decrease in extracellular glucose 
concentration and regulate glucose transport in a glucose limited environment (Ozcan et 
al., 1996a, Ozcan et al., 1998, Ozcan et al., 1996b). However, overexpression of the 
low affinity transporters Pho87 and Pho89 that do not share significant amino acid 
similarity with Pho84 repressed the constitutive phenotype of the pho84 mutant (Wykoff 
and O'Shea, 2001) indicating that an increase in Pi uptake represses the PHO pathway 
and it can occur independent of PHO84 . Therefore, it appeared unlikely that Pho84 is a 
key Pi sensor for the PHO pathway. 
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To identify missing factors involved upstream signaling of the PHO pathway, 
Huang et al. performed a high-throughput and quantitative enzymatic screen of a yeast 
deletion collection (Winzeler et al., 1999) searching for novel mutants defective in 
expression of PHO5 (Huang and O'Shea, 2005). From this screening, nine genes that 
had not been previously known to regulate PHO5 expression were identified. Five 
genes were functioned downstream of the Pho80/Pho85/Pho81 complex and were 
known to be involved in other cellular signaling pathways such as alanine metabolism 
and glucose repression. However, other genes, such as those encoding the adenosine 
kinase Ado1 (Lecoq et al., 2001) and the adenylate kinase Adk1(Konrad, 1988), acted 
upstream of PHO81 and negatively regulated PHO5 expression. The observation that 
the novel genes required for regulation of PHO5 expression were involved in other 
cellular activities suggested that the PHO pathway might be networked with other 
pathways including those involved in purine metabolism. 
 As the genetic screening was not enough to explain how cells sense Pi starvation 
to activate the PHO pathway,  a biochemical strategy was employed as a 
complementary approach to the genetic screening (Lee et al., 2007). A series of 
biochemical assays narrowed down the identity of a regulatory factor for 
Pho80/Pho85/Pho81; IP7, one of inositol polyphosphate metabolites, was identified as a 
signaling molecule for the PHO pathway. The cellular concentration of IP7 increased in 
Pi starvation conditions and an isomer of IP7 generated by the inositol 
hexakisphosphate kinase Vip1 binds to Pho81 and inhibits the kinase activity of the 
Pho80/Pho85 complex both in vivo and in vitro. In the vip1 mutant, Pho4 was not 
localized into the nucleus in Pi starvation conditions, whereas it was constitutively 
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nuclear in the ddp1 (IP7 phosphatase) mutant, which has high levels of IP7 (York et al., 
2005). Pho4 was constitutively in the nucleus in the vip1 pho80 double mutant, but it 
was not detected in the nucleus in the ddp1 pho81 double mutant in Pi starvation 
conditions suggesting that IP7 acts upstream of PHO80  and upregulation of IP7 is 
required for activation of the PHO pathway. 
 Although ADO1, ADK1, and VIP1 were identified as genes involved in signaling 
in the PHO pathway, we still do not understand how they work together to sense Pi 
availability. It was shown that Vip1-synthesized IP7 is upregulated and required for 
inducing the PHO regulon in Pi starvation conditions. However, the initiation signal for 
an increase in IP7 production during Pi starvation is still unknown.  Given that IP7 levels 
are determined by a balance between Vip1 kinase activity and Ddp1 phosphatase 
activity during Pi starvation (York et al., 2005, Lee et al., 2007), there should be a signal 
upstream of IP7 that perturbs the balance between them to make IP7 levels increase in 
low Pi conditions. Furthermore, the molecular mechanism by which ADO1 and ADK1 
repress the PHO pathway in high Pi is unknown and possible connections between 
these kinases’ activities and Vip1 for regulating the PHO pathway have not been 
investigated. 
  
The properties of signaling components of the PHO pathway 
To elucidate how cells sense Pi availability, more signaling factors need to be 
identified. These factors may include small molecules and proteins and should meet two 
criteria. First, their relative abundance or activities should be altered in response to 
changes in Pi concentration. Secondly, they must respond quickly to changes in Pi 
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concentration given that the PHO pathway is activated within 10 minutes in no Pi 
conditions (Zhou and O’Shea, unpublished data).  
As signaling factors, small molecules such as IP7 could interact directly with 
regulatory proteins of the PHO pathway in order to modify their activities. Alternatively, 
these small molecules could regulate proteins that interact with other regulatory proteins 
of the PHO pathway. For example, Pi enhances the kinase activity of Ado1 (Maj et. al., 
2000) that represses the PHO pathway in high Pi conditions. In low Pi conditions, 
however, its kinase activity could be lower than in high Pi due to decreases in Pi 
concentration within the cells resulting from Pi-limited conditions. This decrease in Adk1 
kinase activity could then be a signal for depression of the PHO pathway. It is also 
possible that proteins involved in signaling could generate small molecules regulating 
the PHO pathway. For example, Vip1 synthesizes IP7 whose upregulation is required for 
activating the PHO pathway low Pi conditions. Therefore, to better characterize the 
molecular mechanism of sensing Pi availability, we need to explore both small 
molecules and proteins as signaling factors.  
I sought new components of the PHO pathway using genome-wide genetic 
screening. However, as previous genome-wide genetic screens (Huang and O'Shea, 
2005) identified only a few genes as signaling candidates, I need to design screening 
experiments to cover as much of the genome as possible and utilize a more reliable and 
sensitive phenotype as a screening readout. In chapter 2, I will describe the design of a 
genome-wide genetic screen using a more sensitive and quantitative reporter than that 
of Huang et al. As the outcome of this screening, I report a list of novel genes defective 
in regulation of the PHO pathway and the functional relationships among them.  
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To identify any novel small molecules that regulate the PHO pathway, I 
investigated the metabolic responses to changes in extracellular Pi concentration. Given 
that deletion of ADO1, ADK1, and AAH1 – genes involved in the purine metabolism - 
constitutively activates the PHO pathway, regulation of the PHO pathway may be 
associated with changes in purine metabolism.  Furthermore, it was previously shown 
that an increase in IP7 abundance regulates the PHO pathway in Pi-limited conditions. 
Recent technical advances in mass spectrometry (MS) coupled with liquid 
chromatography (LC) enable me to detect many metabolites simultaneously (Fiehn et 
al., 2000, Raamsdonk et al., 2001, Ejsing et al., 2009) and to generate a comprehensive 
picture of how the metabolome is rearranged under conditions in which environmental 
nutrient levels vary (Brauer et al., 2006). Based on the response times and amplitudes 
of metabolites in changing Pi concentrations, I provide insights into which metabolites 
could be regulatory signals for the PHO pathway. In chapter 3, I will describe how the 
metabolome of Saccharomyces cerevisiae varied over time in Pi-starved and 
replenished conditions.  
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Chapter 2 
Genome-wide Genetic Screening to Identify Novel Genes Involved in Signaling of 
the PHO Pathway 
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Rationale 
 In response to Pi limitation, Saccharomyces cerevisiae induces the transcription 
of a set of genes that are essential for maintaining intracellular Pi concentrations. The 
PHO pathway mediates this response through a cyclin/cyclin-dependent kinase (CDK) 
/CDK inhibitor complex, Pho80/Pho85/Pho81 complex. While the molecular mechanism 
by which the core complex regulates the transcription of the PHO regulon in response to 
changes in extracellular Pi concentration is well understood, little is known about how 
cells sense changes in environmental Pi availability.  Previous work identified three 
signaling factors upstream of the Pho80/Pho85/Pho81 complex: the adenosine kinase 
Ado1, the adenylate kinase Adk1, and the inositol hexakisphosphate kinase Vip1 (Lee 
et al., 2007, Huang and O'Shea, 2005). However, it is still not known how these 
signaling factors are interconnected to regulate the PHO pathway. Specifically, we do 
not know how Ado1 and Adk1 regulate the PHO pathway depending on the Pi 
concentration or how IP7 is upregulated in Pi-limited conditions.  Given that Ado1, Adk1, 
and Vip1 appear to be under the control of other regulatory proteins that are not known, 
it is desirable to screen for those additional genes and identify the functional 
relationships among them.  
To address these issues, I exploited synthetic genetic interaction screens as a 
means of identifying functional relationships among the genes of interest (Jonikas et al., 
2009, Collins et al., 2007). The relationships can be inferred by comparing the 
phenotype of a double mutant and its constituent single mutants and estimating the 
extent to which deletion of one gene modulates the phenotype of a second deletion. For 
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example, synthetic lethality occurs when each mutant is viable and the combination of 
two mutations leads to an inviable organism. This interaction between the two genes 
suggests that their gene products buffer one another for the essential function. Because 
this screening technique allows us to generate double mutants carrying all possible 
combinations of single mutations of interest by crossing them in parallel (Tong et al., 
2004), a large-scale mapping of functional relationships between genes can be obtained.   
In this chapter, I described how I performed genome-wide genetic screening and 
report a list of novel genes whose deletion leads to defects in the regulation of the PHO 
pathway. Furthermore, I identified unappreciated genetic interactions among the 
identified genes. 
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Results 
Determination of mutants defective in PHO84 expression levels acting upstream 
of PHO80 or PHO81 from genome-wide genetic screening 
Genome-wide screens with a yeast deletion library were performed to identify genes 
that affect PHO pathway activity and act upstream of PHO80 or PHO81. The activity of 
the PHO pathway in each mutant was monitored by a fluorescent gene expression 
reporter driven by the PHO84 promoter, which is induced in low Pi (see “Quantification 
of PHO84 expression level of the single mutant“). The phenotypes of all the mutants in 
the library were measured in both low and high Pi conditions to determine if the PHO 
pathway is misregulated in the mutant strain - either less activated than the wild type 
strain in low Pi (weakly inducible mutant) or inappropriately activated in high Pi 
(constitutively induced mutant), (see “Pi concentrations for screening”). Statistical 
analysis was performed to quantify how significantly each sample’s phenotype deviated 
from that of the wild type strain (see "p-value analysis to determine the first hits” in 
Material and Methods). From this initial screening, 445 weakly inducible mutants and 
280 constitutively induced mutants with a p-value< 0.001 were identified (Figure 2.1).  
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Figure 2.1. Identification of mutants showing phenotypes deviating from wild type in low 
and high Pi. (A) The distribution of PHO84 expression levels of all the single mutants in 
50 uM Pi. All the phenotypes are normalized to wild type in 50 uM Pi. The mutants 
showing lower PHO84 expression levels than wild type in 50 uM Pi are defined as 
weakly inducible hits. (B) The distribution of PHO84 expression levels of all the single 
mutants in 1 mM Pi. All the phenotypes are normalized to wild type in 1 mM Pi. The 
mutants showing higher PHO84 expression levels than wild type in 1 mM Pi are defined 
as constitutively induced hits. The red bars in each diagram indicate the maximum and 
minimum PHO84 expression levels satisfying the p-value of measurement errors <0.001. 
The mutants in red are previously identified as uninducible (A) and constitutively 
induced mutants (B), respectively. 
 
To identify genes acting upstream of PHO80 or PHO81, a double mutant 
analysis was performed on all 725 hits identified in the initial screening. It is known that 
the pho80 mutant constitutively activates the PHO pathway, whereas the pho81 mutant 
is uninducible in low Pi conditions (Schneider et al., 1994, Kaffman et al., 1994).  In 
principle, if the weakly inducible mutants act upstream of PHO80, the 445 double 
mutants carrying the pho80 mutant are expected to have the same phenotype as the 
pho80 single mutant. Given that the pho80 mutant phenotype is so strong, it was 
difficult to detect a decrease in PHO84 expression levels due to deletion of the weakly 
 15 
 
inducible genes even if the defect exists. To circumvent this potential problem, I used a 
partial loss of function pho80 DAmP allele – instead of the pho80 deletion mutant - 
which reduces the stability of PHO80 transcripts significantly. (See “Double mutant 
analysis to identify genes upstream of PHO80 and PHO81”). From this analysis, 362 of 
the 445 weakly inducible mutants appeared to act upstream of PHO80 (Figure 2.2.A). 
Similarly, if the constitutively induced mutants act upstream of PHO81, I expect the 280 
double mutants carrying the pho81 mutant to show the same phenotype as the pho81 
single mutant. For the constitutively induced mutants, most of them showed very similar 
PHO84 expression levels to the pho81 single mutant (Figure 2.2.B). Therefore, all of the 
280 constitutively induced mutants appeared to act upstream of PHO81. In view of the 
high number of genes identified as acting upstream of PHO80 and PHO81, the 
stringency of the initial genome-wide screen was increased to focus on the genes 
having a profound effect. I selected only genes showing at least a two-fold decrease or 
increase in the PHO84 expression levels compared to the wild type in low and high Pi 
conditions, respectively. Among the 362 weakly inducible and 280 constitutively induced 
mutants, 310 weakly inducible and 30 constitutively induced mutants met those criteria, 
respectively (Supplementary table 2.1 and 2.2).  
Among the top 30 constitutively induced mutants, there are seven genes whose 
deletion leads to more than a 10-fold induction of PHO84 expression compared to the 
wild type in high Pi conditions. Interestingly, three of the seven genes are involved in 
purine metabolism (AAH1, ADO1 and ADK1; Supplementary table 2.1). It was 
previously reported that deletion of ADO1 and ADK1 leads to a constitutively induced 
PHO phenotype in high Pi (Huang and O'Shea, 2005). In this screen, both of the ado1 
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and adk1 mutants induced PHO84 expression about 45 times more than the wild type 
strain in high Pi conditions (Figure 2.1. B, Supplementary table 2.1). Deletion of AAH1, a 
gene encoding a deaminase that converts adenine into hypoxanthine, induced PHO84 
expression about 30 times more than the wild type strain in high Pi conditions (Figure 
2.3.B). The identification of another gene involved in purine metabolism highlights the 
potential importance of this pathway in the Pi starvation response. For this reason, in 
chapter 3, I measured the abundances of purine metabolites in purine metabolism 
mutants affecting the PHO pathway (AAH1, ADO1 and ADK1) in high Pi as well as the 
wild type in low Pi.     
Huang et al. have shown that both ADO1 and ADK1 act upstream of PHO81 
(Huang and O'Shea, 2005). To determine if this is also the case for the aah1 mutant, 
the aah1 pho81 double mutant was generated and its PHO84 expression levels were 
measured. As expected, the constitutively activated phenotype of aah1 mutant was 
suppressed in the aah1 pho81 double mutant suggesting that AAH1 also acts upstream 
of PHO81 (Figure 2.3.E). 
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Figure 2. 2. Identification of genes upstream of PHO80 and PHO81. (A) The histogram 
of normalized reporter levels of double mutants carrying all the weakly inducible hits and 
the pho80 DAmP in 50 uM Pi. The first value in the parentheses is the phenotype of a 
weakly inducible single mutant normalized to wild type in 50 uM Pi. The second value in 
the parentheses is the phenotype of a double mutant carrying the weakly inducible 
mutant and the pho80 DAmP normalized to pho80 DAmP in 50 uM Pi. (B) The 
histogram of normalized reporter levels of double mutants carrying all the constitutively 
induced hits and the pho81 mutant in 1 mM Pi. The first value in the parentheses is the 
phenotype of a constitutively induced single mutant normalized to wild type in 1 mM P i. 
The second value in the parentheses is the phenotype of a double mutant carrying the 
constitutively induced mutant and the pho81mutant normalized to the pho81 mutant in 1 
mM Pi. Genes in blue and red are previously identified as upstream and downstream of 
PHO80 or PHO81, respectively. 
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Figure 2.3. The raw PHO84 expression levels of the purine metabolism mutants and the 
aah1 pho81 double mutants in 1 mM Pi. PHO84 and constitutive TEF2 promoters drive 
YFP and RFP expressions, respectively. The PHO84 expression levels of single cells 
were quantified as log2 intensity ratios of YFP to RFP. (A) Wild type, (B) the aah1 
mutant, (C) the adk1 mutant, (D) the ado1 mutant, and (E) the aah1 pho81 double 
mutant in 1 mM Pi, respectively. (F) The adenine nucleotide metabolism pathway. Red 
rectangles indicate the identified genes in this screen. This diagram is credited with 
Lecoq et al. (Lecoq et al., 2000). 
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Novel phenotype of the vip1 mutant in prolonged Pi starvation 
 In 2007, Lee et al. showed that deletion of VIP1 leads to an uninducible 
phenotype suggesting a role for Vip1- synthesized IP7 in the Pi starvation response (Lee 
et al., 2007). In the genome-wide single mutant analysis, I observed that the vip1 
mutant was able to activate the PHO pathway upon prolonged Pi starvation. The vip1 
mutant induced PHO84 expression 65% less than the wild type when it was grown in 
low Pi for eight hours (Supplementary table 2.2). At first, this result was surprising 
because it seemed inconsistent with the study mentioned above (Lee et al., 2007). In 
the view of the two different Pi starvation durations used in the two studies, one possible 
explanation is that the induction of the PHO pathway in the vip1 mutant is slower than in 
the wild type rather than completely absent. To test this hypothesis, a kinetic assay for 
PHO84 expression in the vip1 mutant was performed. The wild type induced PHO84 
expression in one hour in low Pi, whereas the vip1 mutant showed PHO84 expression 
only after four hours (Figure 2.4). This suggests that the vip1 mutant is kinetically 
defective in regulation of the PHO pathway and eventually partially activates the PHO 
pathway in prolonged Pi starvation. 
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Figure 2. 4. The PHO84 expression time course measurements of wild type and the 
vip1 mutant in 50 uM Pi. (A, C, E) The PHO84 expression levels of the wild type in 1, 2, 
and 4 hours, respectively.(B, D, F) The PHO84 expression levels of the vip1 mutant in 1, 
2, and 4 hours, respectively. Refer Figure 2.3.A to the PHO84 expression levels of wild 
type in 1 mM Pi.  
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Identification of novel genetic interactions with the purine and inositol 
polyphosphate metabolism pathway components  
As shown in a previous section, the genome-wide genetic screen identified 310 
weakly inducible mutants and 30 constitutively induced mutants acting upstream of 
PHO80 and PHO81. Furthermore, it has been shown here and by others that the purine 
metabolism genes ADO1, AAH1 and ADK1 and also VIP1 are involved in signaling in 
the PHO pathway upstream of Pho80/85/81 (Huang and O'Shea, 2005, Lee et al., 2007). 
In order to investigate the functional relationship between the 340 genes identified in the 
screens and the four genes mentioned above, double mutants of the 340 genes with 
ADO1, AAH1 and ADK1 and also VIP1 were constructed and their PHO84 expression 
levels were measured in high and low Pi conditions. The goal of this double mutant 
screen was to identify genes that perturb the constitutively activated phenotype of the 
three purine metabolism mutants or the weakly inducible phenotype of the vip1 mutant. 
For example, if a gene is required for the constitutively induced phenotype of the ado1 
mutant, a double mutant carrying both mutants should be unable to express PHO84 in 
high Pi. On the other hand, if two weakly uninducible mutants show similar PHO84 
expression levels to the wild type in low Pi and the double mutant carrying both mutants 
is uninducible, it shows that one gene can compensate for the loss of the other gene. 
This relationship indicates that the two genes act in parallel (Tong et al., 2004) in terms 
of regulation of the PHO pathway. 
To identify which genes are required for the constitutive PHO phenotype of the 
purine metabolism mutants, double mutants of all 340 identified single mutants from the 
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initial screening with the ado1 or the aah1 mutant were generated and their PHO84 
expression levels in high Pi were measured. The double mutants carrying deletion of 
ADK1 could not be generated for technical reasons (see “Making double mutants with 
the array strains”). Among each set of 340 double mutants of the aah1 and the ado1 
mutants, there were 51 and 18 uninducible double mutants in the aah1 and ado1 
analysis, respectively. (Figure 2.5.A and B, Supplementary table 2.4, 2.5). Moreover, as 
seen in Table 2.1., nine genes were shared between the two groups of double mutants 
indicating that these ten genes are required for the constitutively induced phenotype of 
both the ado1 and the aah1 mutants in high Pi. I investigated common features of the 
ten genes to find their functional relationships with purine metabolism, but found no 
obvious common feature among them. The function of three genes YJL175W, OPI11, 
YPR045C are unknown and four genes (TMA23, TRM9, RSA1, KTI11) are related to 
transcription or translational machinery. It is not clear why these eight genes are 
required for the constitutively activated phenotype of the aah1 and ado1 mutants. 
Interestingly, however, the aah1 vip1 and the ado1 vip1 double mutants repressed the 
constitutively activated phenotype of the aah1 and the ado1 single mutants, indicating 
that VIP1 is required for the constitutively activated phenotype of the ado1 and the aah1 
mutants (Figure 2.5.C.). This is consistent with the observation that IP7 was upregulated 
in the ado1 and the adk1 mutants in high Pi (10 mM) (Lee and O’Shea, unpublished 
data). Therefore, it appears that VIP1 is downstream of ADO1 and AAH1 when the two 
gene products repress the PHO pathway in high Pi.  
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Table 2.1. List of genes whose double mutants with both ado1 and aah1 mutants are 
uninducible. Reporter levels of all the mutants are normalized to the wild type in 50 uM 
Pi. The reporter level of wild type in high Pi is -4.5. Uninducible double mutants were 
chosen as the ones whose reporter level is lower than -4.  
Gene normalized 
log2(YFP/RFP) to 
wild type in 50 uM Pi 
as a single mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of aah1 
mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of ado1 
mutant 
VIP1 -1.66 -6.48 -4.47 
YJL175W -5.14 -5.91 -4.47 
PHO81 -5.75 -5.48 -5.16 
OPI11 -4.73 -5.45 -5.60 
TMA23 -3.91 -5.39 -4.55 
TRM9 -4.38 -5.34 -5.37 
YPR045C -2.85 -5.10 -5.79 
RSA1 -3.77 -4.89 -5.25 
KTI11 -1.58 -4.31 -4.31 
 
 
To identify genes that can compensate for the absence of Vip1-synthesized IP7 
to activate the PHO pathway in prolonged Pi starvation, double mutants of all 340 
mutants identified as acting upstream of PHO80 or PHO81 with the vip1 and the ipk1 
mutants were measured in low Pi (Figure 2.6.A and B.). IPK1 encodes an inositol 
pentakisphosphate (IP5) kinase whose substrate is a precursor of IP7 synthesis (Ives et 
al., 2000). Like the vip1 mutant, the ipk1 mutant showed no detectable IP7 levels and 
did not activate the PHO pathway early in Pi-starvation (Lee et al., 2007). Among each 
set of 340 double mutants of the vip1 and the ip1k mutants, there were 80 and 40 
uninducible double mutants carrying deletion of VIP1 and IPK1, respectively (Figure 
2.6.A and B., Supplementary table 2.6 and 2.7). From those uninducible double mutants, 
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as seen in Table 2.2., there were 11 genes whose single mutants were weakly defective 
in activation of the PHO pathway but were uninducible as double mutants of both the 
vip1 and the ipk1 mutants. The function of six genes (YGR160W, YLR184W, 
YMR242W-A, YGL188C-A, FYV1, BUD28) are unknown and two genes (ARP8 and 
MET18) are related to transcription or translational machinery. Although it is not clear 
how IP7 synthesis can be related to the functions of the ten genes, the three genes 
(MCT1, HTD2, and PDB1) share common defects in converting pyruvate into acetyl-
CoA upon their deletion. The relationships between Vip1-synthesized IP7 and these 
three genes are presented in the discussion. 
 
Table 2.2. List of genes whose double mutants with vip1 and ipk1 mutants are 
uninducible in 50 uM Pi. Reporter levels of all the mutants are normalized to the wild 
type in 50 uM Pi .The reporter level of wild type in high Pi is -4.5. Weakly inducible 
single mutants were chosen as the ones whose reporter level is higher than -2. 
Uninducible double mutants with the ipk1 and vip1 mutant were chosen as the ones 
whose reporter level is lower than -4. 
Gene normalized 
log2(YFP/RFP) to 
wild type in 50 uM Pi 
as a single mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of vip1 
mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of ipk1 
mutant 
YGR160W -1.06 -5.74 -5.28 
YLR184W -1.08 -6.25 -5.52 
HTD2 -1.16 -4.78 -4.76 
PDB1 -1.30 -5.48 -4.27 
YMR242W-A -1.32 -6.23 -5.83 
ARP8 -1.54 -5.42 -4.12 
YGL188C-A -1.55 -6.56 -5.37 
FYV1 -1.80 -4.42 -4.12 
MET18 -1.89 -6.01 -5.17 
MCT1 -1.94 -5.24 -5.13 
BUD28 -1.99 -6.08 -5.29 
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Figure 2.5. Double mutant (DM) plot of (A) the aah1 and (B) the ado1 mutant in 1 mM Pi. 
Each point represents a gene identified as involved in regulation of the PHO pathway 
upstream of PHO80 or PHO81. X coordinate represents the reporter level of a strain 
deleted for that gene in the wild-type (WT) background. Y coordinate represents the 
reporter level in a double mutant lacking the same gene and additionally deleted for 
AAH1 and ADO1, respectively. All the phenotypes of single and double mutants were 
normalized to wild type in 50 uM Pi. The normalized phenotype of wild type in 1 mM Pi 
(no activation of the PHO pathway) is -4.5. The horizontal red line in each diagram 
indicates the normalized phenotype of the aah1 and ado1 single mutant in 1 mM Pi, 
respectively.(C) The raw PHO84 expression levels of the aah1 vip1 (left) and the ado1 
vip1 (right) double mutants in 1 mM Pi. Refer Figure 2.4.A to the PHO84 expression 
levels of wild type in 1 mM Pi. 
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Figure 2.6. DM plot of (A) the vip1 and (B) the ipk1 mutant in 50 uM Pi. The horizontal 
red line in each diagram indicates the normalized phenotype of vip1 and ipk1 mutant in 
50 uM Pi, respectively. (C) Raw PHO84 expression level of the vip1 htd2, vip1 mct1, 
and vip1 pdb1 double mutants. Refer Figure 2.4.A to the PHO84 expression levels of 
wild type in 1 mM Pi. 
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Discussion  
In this study, I identified more than 300 novel single mutants that are defective in 
regulation of the PHO pathway, a much larger number than was identified in the 
previous genome-wide screening (Huang and O'Shea, 2005). Because the screening 
was performed under milder conditions than Huang et al (50 uM and 1 mM Pi versus no 
and 10 mM Pi), genes that are weakly involved in regulation of the PHO pathway - such 
as those that only shift an activation threshold - could be detected. Synthetic gene array 
(SGA) (Tong and Boone, 2006) screens made it possible to insert a fluorescence 
reporter in the entire yeast deletion library and to generate massive numbers of double 
mutants in order to compare the phenotypes of double mutants to their constituent 
single mutants.  
In this screen, a purine metabolism gene AAH1 was identified as acting upstream 
of PHO81. Combined with the knowledge that the ado1 and adk1 mutants are also 
involved in the purine metabolism and are constitutively induced mutants acting 
upstream of PHO81, the discovery of the aah1 mutant phenotype supports the idea that 
regulation of the PHO pathway could be associated with changes in purine metabolism. 
Because the role of ADO1 and ADK1 in purine metabolism is not clear, measuring the 
purine metabolism response during a transition from high to low Pi conditions may 
provide insights into details of the upstream PHO pathway. There is an exciting 
possibility that purine metabolites could trigger the response of the PHO pathway to 
changes in Pi concentrations. In chapter 3, I measured the metabolomic response to 
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changes in Pi concentration and observed variations in purine metabolism in different Pi 
concentrations. 
I showed that the vip1 mutant activated the PHO pathway slowly compared to the 
wild type in low Pi conditions. This aspect of the phenotype of the vip1 mutant could 
explain why VIP1 was not identified in the previous screening (Huang and O'Shea, 2005) 
as being defective in signaling of the PHO pathway. The conditions used by Huang et al. 
in their screening do not allow the identification of mutants which have a kinetic defect in 
regulation of the PHO pathway.  Therefore, it is likely that the vip1 mutant did not meet 
the chosen criteria for uninducible mutants. 
To quantify genetic interactions, we should define a neutrality function that 
predicts the quantitative phenotype of double mutants carrying two non-interacting 
mutations (Mani et al., 2008). If the phenotype of interest is a growth defect in mutants, 
it was shown that in the absence of a genetic interaction the growth defect of a double 
mutant is expected to be the product of the individual  growth defects of the constituent 
single mutants (Boone et al., 2007, Segre et al., 2005) . However, a neutrality function 
for gene expression levels as a quantitative phenotype is not well defined and it was 
difficult to find a neutrality function for my data between the phenotype of a double 
mutant and its non-interacting corresponding single mutants. However, extreme genetic 
interactions - such as complete repression of a constitutive single mutant phenotype as 
a double mutant - are easily detectable and their interpretation is straightforward.  The 
10 genes in Table 2.1 are required for the constitutive phenotype of purine metabolism 
mutants. One interesting gene required for the constitutive phenotype of aah1 and ado1 
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mutants is VIP1. The vip1 aah1 and vip1 ado1 double mutants do not constitutively 
activate the PHO pathway (Figure 2.5.C). This implies that purine metabolism and IP7 
synthesis may be interconnected to repress the PHO pathway in high Pi conditions 
(Figure 2.8). To investigate this relationship, I performed in chapter 3 metabolic profiling 
of the aah1, vip1 aah1, ado1, vip1 ado1 mutants in high Pi conditions and compared the 
adenine nucleotide levels of all mutants. 
  The delayed activation of the PHO pathway in the vip1 mutant in prolonged Pi 
starvation suggests two possible mechanisms: synthesis of IP7 in the absence of Vip1 or 
a novel mechanism that regulates Pho81 activity without IP7. To resolve this conundrum, 
it is crucial to measure IP7 levels in the vip1 mutant in a long period of Pi starvation. If 
IP7 is observed in the vip1 mutant, there must be a novel pathway synthesizing IP7 
without Vip1. In this work, a number of the double mutants carrying the vip1 mutant that 
are completely uninducible in low Pi conditions upon prolonged starvation were 
identified (Table 2.2). If another gene is capable of synthesizing IP7 in the absence of 
Vip1, it is expected that a double mutant of both genes should be uninducible. This 
raises the exciting possibility that one of the 13 genes mentioned in Table 2.2 could be 
crucial for the synthesis of IP7 in the absence of Vip1. Among the 13 genes, two genes 
HTD2 (mitochondrial 3-hydroxyacyl-thioester dehydratase) and MCT1 (a component of 
a type-II mitochondrial fatty acid synthase) are involved in mitochondrial fatty acid 
biosynthesis (mtFAS) (Figure 2.7.) (Kastaniotis et al., 2004, Schneider et al., 1997). 
Given that only three mtFAS genes (MCT1, HTD2, and CEM1) are included among the 
identified single mutants in this screen, it is statistically significant that two genes MCT1 
and HTD2 interacting with both VIP1 and IPK1 are involved in the mtFAS pathway (p-
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value =1.81*10-9). Based on the observation that lesions within the mtFAS pathway 
exhibited low levels of lipoic acid (Brody et al., 1997), it was suggested that the major 
role of mtFAS is to provide octanoate which serves as a precursor for lipoic acid 
(Hiltunen et al., 2009, Tehlivets et al., 2007). In the presence of lipoic acid, pyruvate 
dehydrogenase (PDH) can convert pyruvate into acetyl-CoA.  Given that Pdb1 is the E1 
beta subunit of PDH and the vip1 pdb1 and the ipk1 pdb1 double mutants were 
uninducible in low Pi (Table 2.3), the uninducible phenotypes of the double mutants 
carrying the htd2, mct1, and pdb1 mutants appear to be associated with defects in 
acetyl-CoA biosynthesis (Figure 2.7). In chapter 3, I showed that phosphatidylcholine 
(PC), a major membrane phospholipid, was downregulated in low Pi conditions. Given 
that phospholipids contain two fatty acid chains and acetyl-CoA is a C2-carbon donor of 
fatty acid biosynthesis, it is conceivable that activation of the PHO pathway in the vip1 
mutant in prolonged Pi starvation is associated with changes in fatty acid metabolism 
(Figure 2.8). Interestingly, disruption of the mtFAS pathway in Trypanosoma brucei 
resulted in changes in the composition of cellular phospholipids (Guler et al., 2008). The 
phospholipid Inositol 1,4,5-trisphosphate (IP3) is a precursor of IP7 synthesis 
(Monserrate and York, 2010) and is generated by hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2), a minor phospholipid component of cell membranes (York, 2006). 
This relationship between inositol polyphosphate and phospholipid metabolism 
suggests that activation of the PHO pathway in the vip1 mutant in low Pi conditions 
could be coupled with changes in phospholipid metabolism.  
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Figure 2.7. MCT1 and HTD2 are involved in mitochondrial fatty acid synthesis (p-value 
= 1.81*10-9).The major role of this pathway is to provide octanoyl-ACP which serves as 
a precursor for lipoic acid. Lipoic acid is required for converting pyruvate into acetyl-CoA 
mediated by pyruvate dehydrogenase (PDH).  
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Figure 2.8. Novel genetic interactions among the genes acting upstream of PHO80 and 
PHO81. The blue ovals indicate the genes whose deletion leads to constitutively 
activated PHO pathway. The purple ovals indicate the genes whose deletion leads to 
defective in induction of the PHO pathway in low Pi. 
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Materials and methods 
Strains 
All the strains used in this study were in the BY4741 strain background (MATa 
his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) and are listed in Table 2.3. Gene deletions were 
introduced by transformation of gel-purified PCR products consisting of a nourseothricin 
marker (NatR) flanked at each end by 40 base pair (bp) homologous to the upstream 
and the downstream region of the targeted open reading frame. The transformation was 
followed by selection on a YEPD+Nat growth medium. All the mutations shown in this 
work are ablations of the open reading frame except the pho80 DAmP (Decreased 
Abundance by mRNA Perturbation) strain. To make the pho80 DAmP strain, a PCR 
product including a Nat marker was introduced after the stop codon and selected on 
YEDP+Nat media. The cassette for the PHO84 reporter strain was generated by a 
series of fusion PCRs with 1 kb of PHO84 promoter sequence, Venus fluorescence 
protein, and the sequence of TEF2 promoter-RFP-MET15-URA3 from yMJ003.  
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Table 2.3. Strains used in this study 
Strain Genotype Reference 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 (Brachmann 
et al., 1998) 
yMJ001 MATα his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 LYS+ 
Δcan1::STE2pr-spHIS5 Δlyp1::STE3pr-LEU2 cyh2 
(Jonikas et 
al., 2009) 
yMJ003 MATα his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 LYS+ 
Δcan1::STE2pr-spHIS5 Δlyp1::STE3pr-LEU2 cyh2 
Δura3::UPRE-GFP-TEF2pr-RFP-MET15-URA3 
(Jonikas et 
al., 2009) 
PHO84 
reporter  
MATα his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 LYS+ 
Δcan1::STE2pr-spHIS5 Δlyp1::STE3pr-LEU2 cyh2 
Δura3::PHO84pr-Venus-TEF2pr-RFP-MET15-URA3 
This study 
vip1::NatR MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δvip1::NatR This study 
ipk1::NatR MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δipk1::NatR This study 
aah1::NatR MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δaah1::NatR This study 
ado1::NatR MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δado1::NatR This study 
pho81::NatR MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δpho81::NatR This study 
pho80 DAmp See “Strains” This study 
 
Insertion of the PHO84 expression reporter into a yeast library 
 Using the Synthetic Genetic Array strategy (SGA) (Tong et al., 2001), the PHO84 
reporter strain was mated to approximately 6100 MATa strains in a deletion library 
(Jonikas et al., 2009) in addition to DAmP strains for essential genes (Breslow et al., 
2008). The protocol I used was similar to the one described by (Schuldiner et al., 2005). 
The major difference between the two protocols is that MATα - not MATa- haploids were 
selected as final haploid strains having both the PHO84 expression reporter and 
deletion of a gene. This allowed subsequent mating of the final haploid strains to 
another deletion strain of interest in order to generate double mutants. (see “Making 
double mutants with array strains” below). After haploid selection, strains were grown 
twice on SD(MSG) –LEU –ARG –LYS +can +S-AEC +G418 –URA plates to select for 
 35 
 
MATα strains carrying the PHO84 reporter and Kan-marked deletions (Tong and Boone, 
2006). 
 
Pi concentrations for screening 
 50 uM and 1 mM Pi were chosen as low and high Pi conditions, respectively. It 
was known that there are two populations of cells over a range of Pi concentrations from 
100 to 200 uM (intermediate Pi): one that expresses little PHO84 (off-population) and 
another that highly expresses PHO84 (on-population) (Wykoff et al., 2007). Because the 
relative portion of off- and on-population is sensitive to small changes in Pi, intermediate 
ranges of Pi were avoided. In order to identify mutants showing subtle defects such as 
different threshold to activate or repress the PHO pathway, mild conditions -50 uM and 
1 mM Pi - for inducing and repressing the PHO pathway were chosen. 
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Figure 2.9. Preparation of samples to measure reporter levels in flow cytometry 
 
Measurement of reporter levels 
Reporter levels were measured by flow cytometry using YFP and RFP channels. 
All cell cultures were grown in synthetic complete medium at 30ºC in a 384 well-plate on 
a plate shaker. Strains were inoculated from the final haploid selection agar plate to 
384-well liquid cultures of 80 ul/well SD complete medium with 10 mM Pi concentration 
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(Figure 2.9). These cultures were grown overnight and back-diluted 16 times using a 
BioMek FX (Beckman Coulter, Inc.,Fullerton, CA, USA) liquid handling robot in a final 
volume of 80 ul of SD complete no Pi medium in 384-well plates. Subsequently, the 
liquid cultures in no Pi medium were diluted 16 fold in a final volume of 80ul of SD 
complete medium with 1 mM and 50 uM Pi concentration depending on the screening 
conditions. The strains were grown for additional eight hours before measurements 
(Figure 2.9). 
Plates were then transferred to a Becton Dickinson (BD, Franklin Lakes, NJ USA) 
High Throughput Sampler (HTS). The HTS injected cells directly from the wells in which 
they were grown into a LSR Fortessa flow cytometer (BD). The measurement of one 
384-well plate required approximately 110 minutes. The detected number of cells was 
2,000 ~ 6000 cells. Venus was excited at 488nm and fluorescence was collected 
through a 505nm long-pass filter and a HQ515/20 band-pass filter (Chroma 
Technology). mCherry was excited at 532nm and fluorescence was collected through a 
600nm long-pass filter and a 610/20 band-pass filter (Chroma Technology). Each plate 
included two wells containing fluorescent particles (RCP-30-5A, Spherotech) to allow 
compensation for the eventual variation of laser intensity and at least six wells 
containing the PHO84 reporter strain to normalize the fluorescence signals of samples 
to those of the wild type. 
 
Quantification of PHO84 expression level of the single mutant 
Each cell’s intensity in the YFP and RFP channels was used as raw data for 
further processing. To correct for non-reporter-specific variations in single-cell YFP 
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abundance - such as altered translation efficiency caused by deletion of some genes -  
the Venus fluorescence of each cell was normalized to the RFP signal driven by a 
constitutive TEF2 promoter. The average of the log2 YFP/RFP ratios across the cells 
within 30% of the range of top and bottom in a sample was used as the sample’s 
reporter levels in all data shown in this chapter. A customized Matlab code was written 
to analyze “.fcs” data files from the flow cytometer. Samples with low cell counts 
(<300/well) were not used. The reporter levels of each sample were normalized by the 
median of reporter levels of all samples on the same plate to compare the reporter level 
of each strain regardless of different locations on different plates. 
 
p-value analysis to determine if the deviation of measured phenotypes of single 
mutants from that of the wild type is statistically significant 
The distribution of measurement errors was assumed as the sum of two 
Gaussian distributions with different standard deviations and an average of zero. The 
standard deviations were obtained using an iterative fit of the predicted to the actual 
distribution of the difference between replicate measurements of reporter levels in the 
deletion library. The error distribution was used to generate the expected distribution of 
measured values for the wild-type reporter levels. Using this distribution, a p-value 
lookup table was generated: for each reporter level (R) and the number of 
measurements (N), the table estimated the probability of obtaining a reporter levels 
equal to, or more extreme than, R upon the averaging of N independent measurements 
of a wild-type strain. Because I measured all the library plates three times, the possible 
values of N for each sample can equal two or three, depending on the strains. The first 
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weakly inducible candidates were defined as strains with normalized mean intensity 
ratios to the wild type of  < 0 and p-value < 0.001 in 50uM Pi. Similarly, the first 
constitutively induced candidates were defined as mutants with normalized mean 
intensity ratios to the wild type of > 0 and a p-value < 0.001 in 1mM Pi. 
 
Making double mutants with the array strains 
 The protocol used to generate double mutants carrying the array strains and 
deletion of a gene of interest was exactly the same as described in “Insertion of the 
PHO84 expression reporter into yeast library” above except that 100 ug/L nourseothricin 
was included in haploid selection after sporulation to select for MATα strains carrying 
the PHO84 reporter and Kan- and Nat- marked double deletions. The double mutants 
carrying the adk1 mutant could not be generated because germination of haploids after 
sporulation was failed. 
 
Double mutant analysis to identify genes upstream of PHO80 and PHO81 
To generate a mutant defective in Pho80, a pho80 DAmP strain was used 
instead of a pho80 deletion mutant. It was previously known that the PHO pathway is 
activated very strongly in the pho80 deletion mutant, therefore it appeared difficult to 
detect a decrease in PHO84 expression levels due to deletion of the weakly inducible 
genes even if the defect exists. To circumvent that potential problem, I used a pho80 
DAmP strain – instead of the pho80 mutant - which reduces the stability of PHO80 
transcripts significantly.  
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The hypothesis regarding epistasis analysis results with the pho80 mutant was 
checked by previously known mutants acting upstream and downstream of PHO80. The 
same argument can be applied to constitutively induced mutants. If they act upstream of 
PHO81, double mutants carrying pho81 deletion and the constitutively induced hits 
should not be constitutively activated in high Pi conditions. 
To validate the hypothesis that double mutants carrying the pho80 DAmP 
mutation and weakly inducible genes downstream of PHO80 show lower reporter levels 
than the pho80 DAmP strain, double mutants carrying all the first 445 weakly inducible 
hits and the pho80 DAmP mutation were generated through SGA (Tong and Boone, 
2006)  and their reporter levels were compared to that of the pho80 DAmP strain (Fig 
2.3.A). Double mutants with known downstream gene of PHO80 - such as ADA3 and 
SNF2 - showed reporter levels of about two times lower than the pho80 DAmP strain. 
On the other hand, pho81 pho80 and vip1 pho80 double mutants carrying genes 
upstream of PHO80 showed very similar reporter levels (-0.19) to the pho80 DAmP 
strain. To ensure that no possible hits were lost due to a very stringent threshold to 
determine the hits, the maximum reporter level among the double mutants carrying the 
known downstream genes was used to determine if a weakly inducible hit acted 
upstream of PHO80. From this analysis, the first 445 weakly inducible hits were 
narrowed to 362. On the other hand, the epistasis analysis with the pho81 mutant for 
the first constitutively induced hits showed that almost every hit seems to act upstream 
of PHO81 (Fig 2.3.B). Through the two steps, I determined 362 weakly inducible hits 
and 280 constitutively induced hits acting upstream of the core complex. 
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Chapter 3 
Metabolomic Measurements in Response to Changes in Pi Availability 
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Rationale 
Studies have shown that metabolites are involved in regulation of the PHO 
pathway. Deletion of ADO1, ADK1, and AAH1 – genes involved in purine metabolism - 
constitutively activates the PHO pathway. Furthermore, inositol heptakisphosphate (IP7) 
synthesized by Vip1 is required for activating the PHO pathway in Pi starvation 
conditions. Given these observations, it appears that metabolites relevant to these 
pathways are key factors in influencing PHO pathway activity. However, little is known 
about which metabolite is actually responsible for regulation of the PHO pathway. To 
cover as many metabolites as possible, liquid chromatography/ mass spectrometry was 
used to measure scores of metabolites simultaneously in response to changes in Pi 
concentration. Based on dynamic behaviors of metabolites in different Pi conditions, 
potential regulatory signals for the PHO pathway can be detected.  
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Results 
Measuring variations in the metabolome in response to changes in Pi 
concentration 
 To investigate how changes in Pi availability affect a cellular metabolic network, 
metabolomic variations in the wild type were measured over time upon transferring cells 
from high to no Pi (Pi-limited condition), and from no to high Pi (Pi-replenished condition) 
(Figure 3.1, Supplementary table 3.1 and 3.2.). For the measurements in Pi-limited 
conditions, cells were grown in high Pi first , transferred to no Pi, and taken in 2, 5, 10, 
15, 30, 60, and 90 minutes in no Pi. Then, metabolite extractions from the cell cultures 
were carried out at indicated time points and their abundances were measured with 
liquid chromatography coupled with mass spectrometry. For the measurements in Pi-
replenished conditions, cells starved of Pi for one hour first. Then, Pi was added to the 
no Pi cell culture to make high Pi (10 mM Pi) and the cell cultures were taken in 0.5, 1.5, 
3, 5, 10, 15, 30, and 60 minutes in high Pi. The total number of detected metabolites in 
both measurements was 85. When the metabolites were clustered depending on the 
similarity of their dynamic behaviors in different Pi concentrations, two important 
subgroups were identified. First, some metabolites were downregulated quickly in no Pi 
but upregulated again in high Pi. Metabolites involved in purine metabolism, glycolysis 
and the pentose phosphate pathway were included in this subgroup (Figure 3.2.A, B, 
and C). Secondly, some metabolites behaved in an opposite direction from the first 
group: upregulated in no Pi but downregulated in high Pi. S-adenosyl-L-homocysteine 
(SAH), for example, responded the most quickly and significantly to changes in Pi 
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concentration among all the detected metabolites (Figure 3.5.A). When cells were 
transferred from high to no Pi, SAH in no Pi was upregulated about 20 times more than 
in high Pi within two minutes. When Pi was replenished again, however, it was 
downregulated to the similar level to high Pi within one minute. Because metabolites 
involved in regulating the PHO pathway are expected to show a strong correlation 
between their abundance changes with Pi availability, these two groups were 
investigated in detail. 
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Figure 3.1. A heat map display representing yeast metabolome in response to changes 
in Pi concentration. 
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Purine metabolism 
As described in Chapter 2, deletion of the purine metabolism genes ADO1, ADK1, 
and AAH1 leads to constitutive activation of the PHO pathway, which suggests that 
metabolites relevant to purine metabolism may influence PHO pathway activity. The 
purine metabolism response of the wild type to changes in Pi concentration was 
consistent with this hypothesis; most of the detected purine metabolites were 
downregulated in no Pi and were upregulated in high Pi. To test this hypothesis further, 
variations in the metabolome of the wild type upon transferring it from high to no Pi were 
compared to those of all the three purine metabolism mutants in high Pi. The 
abundance of the metabolites regulating the PHO pathway are expected to change in 
no Pi and the same behavior should be observed in all the ado1, adk1, and aah1 
mutants in high Pi. As shown in Figure 3.2.A, all the adenine nucleotides were 
downregulated in both the wild type in no Pi, and all three purine metabolism mutants in 
high Pi. The nucleotide responses of the wild type occurred within two minutes in no Pi, 
which meets the criteria of fast response time as a signaling molecule. Interestingly, the 
responses of nucleosides such as inosine and guanosine in wild type are opposite to 
the purine nucleotides; they were upregulated in no Pi and were downregulated in high 
Pi. On the contrary, there were no consistent behaviors among the mutants; the ado1 
mutant showed downregulation of both inosine and guanosine, whereas the aah1 and 
adk1 mutants showed upregulation of inosine and almost no change in guanosine. 
Putting these observations together, it is conceivable that purine nucleotides could be a 
regulating signal of the PHO pathway reflecting changes in Pi availability. 
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Figure 3. 2. Metabolites that were rapidly downregulated in no Pi and were upregulated 
when Pi is replenished (A) Relative abundance of metabolites in purine metabolism. The 
first three columns represent the data of the constitutively induced mutants involved in 
purine metabolism in 10 mM Pi. The rest of the columns represent the data of  the wild 
type in response to changes in Pi concentration. Each time point of the wild type data is 
the same as Figure 3.1. (B and C) Relative abundance of metabolites in the pentose 
phosphate pathway and glycolysis, respectively. The different colors of ovals and 
rectangles in (B) and (C) indicate detected metabolites corresponding to each color in 
this measurement. Xylulose-5-phosphate and sedoheptulose-7-phosphate are isomers 
and were not distinguishable in this measurement. (n.d.) stands for “not detected”. (D) 
Inhibition of hexokinase by trehalose-6-phosphate. (E and F) The variations in trehalose, 
trehalose-6-phosphate (T6P), and glucose-6-phosphate (G6P) in no and10 mM Pi, 
respectively. 
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Figure 3. 2. (Continued) 
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Figure 3. 2. (Continued) 
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Figure 3. 2. (Continued) 
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Figure 3. 2. (Continued) 
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This hypothesis is also consistent with previously reported chemostat data. Boer 
et al. measured the metabolome of Saccharomyces cerevisiae in steady-state cultures 
in three different limiting nutrients (glucose, ammonium, and Pi) (Boer et al., 2010). In 
their measurement, ATP was strongly decreased, ADP fell only slightly and AMP 
accumulated slightly during phosphorus limitation. Moreover, a low adenylate energy 
charge (AEC) was found selectively in phosphorus limitation. AEC is mainly defined as 
a ratio of ATP to ADP and represents the amount of metabolically available energy 
stored in the adenine nucleotide pool. The strong correlation of ATP concentration and 
AEC with Pi availability in chemostat data suggests that ATP and AEC are reliable 
indicators for phosphorus availability. Given that the PHO pathway is activated in low Pi 
conditions, I hypothesized that variations in ATP levels and/or AEC may be Pi-
dependent regulatory signals for the PHO pathway.   
To test if AEC can reflect the activation of the PHO pathway in low Pi, the AECs 
of the wild type in no Pi were calculated over time (Figure 3.3.A). When extracellular Pi 
concentrations change very rapidly from high to no Pi, there was an initial small rise in 
the AEC for a short period of time; eventually it reached to a similar level to high Pi and 
was steady until 60 minutes. Given that the PHO pathway is already activated in no Pi in 
ten minutes (Zhou and O’Shea, unpublished data), AEC does not appear to be Pi-
dependent regulatory signals for the PHO pathway. 
On the other hand, the AEC correctly predicted the PHO phenotype of single and 
double mutants carrying deletions of ADO1 and AAH1.  As described in Chapter 2, the 
aah1 and ado1 single mutants constitutively activate the PHO pathway (Figure 2.3.B 
 53 
 
and C). However, the aah1 vip1 and ado1 vip1 double mutants repressed the 
constitutively activated phenotype of the aah1 and ado1 mutants, respectively (Figure 
2.5.C). The AECs for the ado1 and aah1 mutants were lower than the wild type in Pi 
starvation for an hour, whereas the ado1 vip1 and the aah1 vip1 double mutants had 
even higher AECs than the wild type in high Pi (Figure 3.3.B). As seen in Figure 3.3.C, 
deletion of VIP1 in the ado1 and aah1 mutants upregulated ATP the most among 
adenine nucleotides and led to an increase in AECs in the double mutants. Combined 
with variations in AECs over time in no Pi, low AEC is sufficient, but not necessary, for 
activation of the PHO pathway.   
Upon Pi limitation, ATP concentration decreased rapidly and the PHO pathway 
was activated. However, it is not clear whether a decrease in ATP level is a causal 
factor activating the PHO pathway or a consequence of cellular adaptation to a Pi-
limited condition. If a decrease in ATP is an activation signal for the PHO pathway, the 
PHO pathway should be activated regardless of Pi concentration when ATP is 
downregulated. This condition can be mimicked by inhibiting glycolysis in high Pi 
because yeast prefers fermentation to respiration for generating ATP in the presence of 
glucose in the growth medium. As phosphorylation of glucose mediated by hexokinase 
is the first step of glycolysis, inhibiting hexokinase activity is expected to lead to a 
decrease in ATP regardless of Pi concentration. An inhibitor of hexokinase, 3-
bromopyruvic acid (3-BrPA) (Pelicano et al., 2006), was introduced in high Pi growth 
medium to reduce ATP concentrations. As a proxy for the activity of the PHO pathway, 
Pho4 nuclear localization and PHO84 expression levels were measured with different 
concentrations of 3-BrPA (see “Measurement of Pho4 nuclear localization” in Methods). 
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Figure 3. 3. Adenylate energy charges (AEC) in response to changes in Pi 
concentration and comparison of AEC among the purine metabolism mutants. (A) AECs 
over time when cells were transferred from 10 mM to no Pi (B) AECs of wild type and 
purine metabolism mutants. The red and blue bars indicate the activated and repressed 
state of the PHO pathway, respectively. (C) The relative abundance of purine 
metabolites in the aah1, the ado1, the aah1 vip1 and the ado1 vip1 mutants in 10 mM Pi. 
Each metabolite is normalized to the corresponding one in the wild type in 10 mM Pi.  
  
In the presence of 3 and 5 mM 3-BrPA in high Pi, cellular ATP levels decreased by 50% 
and 90%, respectively, within 30 minutes (Figure 3.4.A). However, no PHO84 
expression and no discernible nuclear Pho4 and were observed even when 90% of ATP 
was depleted (Figure 3.4.B and C). Given that the extent of decrease in ATP levels in 
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this condition is below the lowest ATP level observed in no Pi, a decrease in ATP levels 
alone does not seem to be a regulatory signal for the PHO pathway. Then, is a 
decrease in ATP levels a consequence of cellular adaptation to Pi starvation? As seen 
in Figure 3.2. B and C, many intermediates in glycolysis and the pentose phosphate 
pathway were downregulated in no Pi. Glycolysis and the pentose phosphate pathway 
are related to purine nucleotide metabolism given that glycolysis is a main route to 
generate ATPs in budding yeast in the presence of glucose in the environment and one 
of the major products of the pentose phosphate pathway is ribose-5-phosphate that is 
required for converting adenine to adenine nucleotide. Therefore, it appears that a 
decrease in ATP levels in no Pi results from downregulation of glycolysis and the 
pentose phosphate pathway.  
The molecular mechanism by which glycolysis and the pentose phosphate 
pathway are downregulated in low Pi conditions appears to be associated with 
downregulation of Glucose-6-phosphate (G6P). Given that G6P lies at the start of 
glycolysis and the pentose phosphate pathway (Figure 3.2.B. and C.), downregulation 
of glucose-6-phosphate seems the most efficient way to downregulate both of the 
metabolic pathways. As seen in Figure 3.2.E and F, trehalose-6-phosphate (T6P), a 
potent hexokinase inhibitor (Figure 3.2.D) (Blazquez et al., 1993), was upregulated in no 
Pi and G6P was downregulated almost at the same time. In Pi-replenished conditions, 
however, T6P was downregulated and G6P was upregulated at the same time. 
Therefore, an increase in T6P in low Pi conditions appears to cause G6P to be 
downregulated, resulting in downregulation of glycolysis and the pentose phosphate 
pathway from their beginning step. 
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Figure 3. 4. The effect of decreases in ATP levels on activation of the PHO pathway. (A) 
Depletion of ATP with 3-bromopyruvic acid (3-BrPA) within 30 minutes. The red 
horizontal line indicates the lowest ATP level measured in no Pi. (B) PHO84 expression 
levels as a function of 3-BrPA concentrations over time. PHO84 expression levels were 
normalized to wild type in 10 mM Pi. (C) No Pho4 nuclear localization was observed in 
the presence of 3-BrPA in 10 mM Pi. (From the left) Pho4 localization in the nucleus in 
10 mM Pi, no Pi, 10 mM Pi with 3 mM 3-BrPA, and 10 mM Pi with 5 mM 3-BrPA. 
 
Changes in the de novo phosphatidylcholine (PC) biosynthesis in response to 
changes in Pi concentration 
In contrast to purine metabolism, glycolysis and the pentose phosphate pathway, 
some metabolites were upregulated quickly in no Pi but downregulated again in high Pi, 
S-adenosyl-L-homocysteine (SAH) was included in this group and responded the most 
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quickly and significantly to changes in Pi concentration among the detected metabolites. 
Upon changing Pi concentration from high to no Pi, SAH was upregulated to a level 
about 20 times more than in high Pi within two minutes. However, SAH was 
downregulated to a level similar to that in high Pi within one minute of Pi replenishment 
(Figure 3.5.A).   
Given the fast time scale and large amplitude variations in response to changes 
in Pi concentration, SAH appears to have an important physiological role associated 
with Pi availability. One possibility is that SAH is a regulatory signal for the PHO 
pathway. To test this hypothesis, Pho4 nuclear localization and PHO84 expression 
levels were measured as a function of SAH concentration in high Pi. Christopher et al. 
showed that simply adding exogenous SAH into the growth medium can lead to an 
increase in intracellular SAH concentrations without changing Pi concentration 
(Christopher et al., 2002). If SAH regulates the activity of the PHO pathway, changes in 
the SAH concentration in the growth medium should activate the PHO pathway 
independent of the actual Pi concentrations. As seen in Figure 3.5.B, C, and D, both 
nuclear Pho4 localization and PHO84 expression levels increased as SAH 
concentration increases, suggesting that the PHO pathway can be activated in a SAH-
dependent manner without changing Pi concentration. However, the extent of activation 
of the PHO pathway with SAH in high Pi was less than that without SAH in no Pi. 
Averaged nuclear Pho4 levels were already saturated in 500 uM SAH but lower than 
those in no Pi (Figure 3.5.C).   
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Figure 3. 5. S-adenosyl-L-homocysteine (SAH) and the activity of the PHO pathway (A) 
SAH response to changes in Pi concentration. (B) The histograms of Pho4 nuclear 
localization intensities in 10 mM Pi with different SAH concentrations. From the left, 
SAH concentrations were 0, 10, 50, 100, 300, 500 uM, respectively. (C) Averaged Pho4 
nuclear localization as a function of SAH concentration.  Pho4 intensity is arbitrary unit 
and the error bar is standard deviation of each SAH concentration. (D) PHO84 
expression levels as a function of SAH concentration in 10 mM Pi.  
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Figure 3. 5. (Continued) 
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Figure 3. 5. (Continued) 
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Accordingly, PHO84 expression levels increased just four times compared to 1 mM Pi 
as opposed to ~80 times in no Pi (Figure 3.5.D). Presumably, the uptake capacity of 
exogenous SAH from the medium was already saturated in 300 uM SAH such that the 
increased intracellular SAH concentration was still lower than that in no Pi. These 
preliminary data are consistent with the hypothesis that an increase in SAH could be an 
activation signal of the PHO pathway.  
 Another possible physiological role for SAH is serving as a signal for regulating 
other cellular reactions utilizing Pi as a substrate. It was previously shown that SAH is a 
potent inhibitor of S-adenosyl-L-methionine-dependent methyltransferases, two of which 
are responsible for de novo synthesis of phosphatidylcholine (PC) (Figure 3.6.A) (Wolfe 
and Borchardt, 1991, Lee et al., 1998). In the absence of choline, sequential 
methylation of phosphatidylethanolamine (PE) is a dominant pathway for PC synthesis 
(Choi et al., 2005, Malanovic et al., 2008). Given that the growth medium in this study 
did not contain choline, a possible working model is that SAH acts as an antagonist of 
de novo synthesis of PC in Pi starvation. To test this model, PC levels in no Pi were 
quantified over time and were shown to be downregulated by 40% within an hour 
(Figure 3.6.B, see “PC quantification”).  
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Figure 3. 6. S-adenosyl-L-homocysteine (SAH) as an inhibitor of de novo 
phosphatidylcholine (PC) biosynthesis (A) de novo PC synthesis via sequential 
methylation of PE; CDP-DG, CDP-diacylglycerol; PS, phosphatidylserine; PE, 
phosphatidylethanolamine; PME, phsosphatidylmonomethylamine; PDE, 
phsosphatidyldimethylamine (B) Relative PC abundance in no Pi over time.  
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Discussion 
Given that the ado1, adk1, and aah1 mutants constitutively activate the PHO 
pathway and they are involved in purine metabolism, measuring changes in purine 
metabolites in different Pi concentrations is of high interest. The metabolomic 
measurements in this study revealed the common features between wild type in no Pi 
and all the three purine metabolism ado1, adk1 and aah1 mutants in high Pi; all adenine 
nucleotides were downregulated. This purine metabolism response is consistent with 
the idea that changes in adenine nucleotides could regulate the PHO pathway. From 
previously reported chemostat experiments during Pi limitation (Boer et al., 2010), it was 
suggested that ATP levels and/or adenylate energy charge (AEC) signals Pi availability. 
Given that the PHO pathway is activated in low Pi, low ATP levels and/or low AEC may 
be initiating a signal of activation of the PHO pathway. However, I showed that a 
decrease in ATP levels alone does not appear to activate the PHO pathway and AEC 
does not change from high to low Pi conditions, implying that those two factors alone 
cannot be triggering signals to activate the PHO pathway. Rather, low levels of all 
nucleotides appear to be the consequence of the downregulation of glycolysis and the 
pentose phosphate pathway in a Pi-limited condition as glycolysis is a major source of 
ATP generation and the pentose phosphate pathway produces ribose-5-phosphate that 
is required for nucleotide synthesis.      
Like purine metabolism, glycolysis and the pentose phosphate pathway were 
downregulated in no Pi. The reason why glycolysis is downregulated in Pi starvation 
may be associated with the mechanism by which glycolysis generates ATPs. The initial 
two steps in glycolysis consume ATP to activate glucose and a surplus of ATP is 
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generated further down the pathway. The first substrate for energy-yielding steps is 
glyceraldehyde-3-phosphate, which reacts with NAD+ and Pi. When Pi starvation makes 
intracellular Pi levels at least transiently low, this reaction may be less favorable due to 
low level of intracellular Pi. In this case, cells may not go through glycolysis to the end 
and just consume ATPs in vain. In order not to waste ATPs in a Pi-limited condition, 
glycolysis may be inhibited from its beginning step, phosphorylation of glucose. Given 
that gluocose-6-phosphate is also the first substrate entering the pentose phosphate 
pathway, the pentose phosphate pathway is also inhibited from the first step during P i 
starvation. Therefore, it appears that downregulation of glycolysis and the pentose 
phosphate pathway in response to Pi starvation is the consequence of the metabolomic 
rearrangements in order to optimize the usage of cellular resources. 
Among detected metabolites, SAH showed the largest variations in response to 
change in Pi concentrations. Given that a metabolite involved in regulation of the PHO 
pathway is expected to show a strong correlation between its abundance and changes 
in Pi availability, I tested the hypothesis that SAH could be a regulatory signal of the 
PHO pathway. As exogenous SAH levels increased in the medium, the PHO pathway 
was activated even in high Pi presumably by increasing cellular SAH levels. This 
preliminary data is consistent with the hypothesis, although it remains uncertain that the 
SAH-dependent activation is relevant to a Pi starvation signal. Given that the pho81 
mutant is uninducible in low Pi, the pho81 mutant is expected to be uninducible with 
SAH if SAH-induced activation is relevant to Pi limitation signal. As a proxy for activity of 
the PHO pathway, Pho4 nuclear localization and PHO84 expression will be measured 
as a function of SAH concentration in the pho81 mutant. 
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Another issue with the SAH-induced activation of the PHO pathway was that the 
extent of the activation induced by exogenous SAH is still lower than that in no Pi. One 
possible explanation is that the increased intracellular SAH concentration by exogenous 
SAH is still lower than the level increased by Pi starvation conditions. Given that the 
SAH hydrolase Sah1 is the only enzyme responsible for degrading SAH in yeast 
(Malanovic et al., 2008), downregulation of Sah1 could increase intracellular SAH 
concentration higher than the maximum level achieved by exogenous SAH. With a 
strain expressing SAH1 under control of the doxycycline-repressible tetO7 promoter, the 
Sah1 level can be titrated as a function of doxycycline. Therefore, the activity of the 
PHO pathway in this strain will be measured as a function of doxycycline concentration 
in high Pi to address this issue. 
In addition to being a possible signaling molecule of the PHO pathway, SAH was 
previously known to inhibit Cho2 and Opi2 which are responsible for de novo synthesis 
of PC (Malanovic et al., 2008). Given that PC biosynthesis is one of the major anabolic 
pathways consuming Pi, it may need to be inhibited to maintain intracellular Pi 
concentration in a low Pi environment. I showed that PC levels decreased in no Pi 
condition, suggesting that PC biosynthesis is regulated by Pi concentration. Given that 
SAH levels were downregulated in Pi replenishment (Figure 3.5.A), PC levels are 
expected to recover in 10 mM Pi. Combined with the changes in PC abundance 
observed in no Pi, the recovery of PC levels in high Pi would be strong evidence that PC 
abundance is regulated by Pi concentration through SAH. For this purpose, experiments 
focused on measuring PC in both 0 and 10 mM Pi are ongoing. Furthermore, as other 
kinds of phospholipids such as phosphatidylserine and phosphatidylethanolamine are 
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precursors of PC biosynthesis (Carman and Han, 2009), it is possible that 
downregulation of PC in low Pi can affect the composition of phospholipids. To 
investigate how cells rearrange the distribution of phospholipids in response to changes 
in Pi concentration, I am working on a global profiling of the lipidome in different Pi 
concentrations. 
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Materials and methods 
Strains 
 All the strains used in Chapter 3 were generated by the same method described 
in Chapter 2. These are the strains used in Chapter 3.  
 
Table 3.1. Strains used in this study 
Strain Genotype Reference 
ado1 vip1 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δvip1::KanR 
ado1::NatR 
This study 
aah1 vip1 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δvip1::KanR 
aah1::NatR 
This study 
Pho4-GFP K699 ade2-1 trp1-1 can 1-100 leu2-3,112 his3-
11,15 ura3 GAL+, PHO4::PHO4-GFP, 
NHP6a::NHP6a-mRFP 
EY2516 
pho81 mutant 
in EY2516 
Δpho81::CgHis  in EY2516 This study 
pho81 mutant  
in PHO84 
reporter 
Δpho81::NatR  in PHO84 reporter This study 
 
Metabolic profiling  
The metabolome of Saccharomyces cerevisiae was characterized as previously 
described (Xu et al., 2012). Briefly, O.D. of 0.3 overnight cultures were diluted 1:70 and 
grown in 10 mM Pi synthetic complete medium in a shaking flask to A600 of ~ 0.2 over 
12 hours. For experiments in no Pi, cells were filtered onto a nylon membrane filter, 
washed with no Pi medium, and transferred into pre-warmed no Pi medium. For 
experiments in Pi replenished conditions, cells starved of Pi for one hour first and 1M 
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KH2PO4 were directly added to the shaker such that the final concentration was 10 mM 
Pi. A portion of the cells (5 mL) were filtered onto the nylon filter, which was immediately 
transferred into - 20°C extraction solvent (40:40:20 acetonitrile/methanol/water). Serial 
extraction was then carried out at indicated time points after cells were transferred to 
different Pi media. Cell extracts were analyzed by reversed phase ion-pairing liquid 
chromatography (LC) coupled with electrospray ionization (ESI) (negative mode) to a 
high-resolution, high-accuracy mass spectrometer (Exactive; Thermo Fisher Scientific) 
operated in full scan mode at 1 s scan time, 105 resolution, with compound identities 
verified by mass and retention time matched to authenticated standard (Lu et al., 2010). 
Isomers are reported separately only where they are fully chromatographically resolved. 
 
Quantification of relative abundance of metabolites and clustering 
To convert raw LC-MS/MS ion counts to relative cellular concentration data, 
ion counts were first normalized by the total number of cells. The typical cell density was 
~ 0.2 and 5 ml of cell culture was used. After normalization, absent values (where no 
peak was detected) and normalized ion counts below 300 were set to 300 to remove 
variations in compounds that were near the limit of detection. The selection of 300 
normalized ion counts as a floor value is based on the lower limit of quantitation typically 
being ~100 ion counts and the smallest normalization factor being around 0.30. 
Normalized ion counts for each metabolite in every sample are provided in 
Supplementary Data 1. Normalized ion counts were then converted to relative 
concentrations by dividing the value for the experimental samples by the corresponding 
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value from 10 mM Pi. All time-point data were sampled twice and each experiment was 
replicated at least once. The average of two time-point data was used to represent each 
time point for one experiment and averaged relative abundance of each experiment was 
used for further analysis. To display the clustered heat map in Figure 3.1., each relative 
concentration was log2 transformed first and hierarchically clustered by metabolite 
using Pearson correlation (Eisen et al., 1998). 
  
Calculation of adenylate energy charge 
 Adenylate energy charge (AEC) is defined as follows: 
AEC = ([ATP]+0.5*[ADP])/([ATP]+[ADP]+[AMP])        (1) 
The absolute concentrations of adenine nucleotides in high Pi were known; [ATP] = 1.93 
mM, [ADP] = 0.491 mM, and [AMP] = 0.0835 mM (Xu and Rabinowitz, unpublished 
data). Using the relative abundance of each purine nucleotide to the wild type in 10 mM 
Pi, AEC was calculated with the equation (1). 
 
Measurement of relative intracellular ATP concentration with 3-BrPA. 
 O.D. 600 of 0.2 of cells grown in 10 mM Pi were transferred into fresh 10 mM Pi 
with 0, 3, 5, 10 mM 3-BrPA and incubated for 30 minutes. Cells were lysed with an ATP 
assay kit (BacTiter-Glo Microbial Cell Viability Assay, Promega) and luminescence was 
measured with Beckman Top counter for one second. The raw intensity was divided by 
 70 
 
the one with no 3-BrPA and the ratio was reported as ATP relative abundance to 10 mM 
Pi. 
 
Measurement of Pho4 nuclear localization  
 Nuclear Pho4 was observed with an inverted fluorescence microscope. The 
nucleus and cytoplasm portion of each cell was segmented with my customized Matlab 
code. The Pho4 nuclear localization signal was defined as a difference in GFP 
intensities between in the nucleus and in the cytoplasm. 
 
PC quantification 
 The protocol to measure PC levels was the same as described in “Metabolite 
measurement” above except for an additional lipid extraction. To extract lipids from cell 
pellets, each was resuspended in 1 mL PBS and transferred into a douncer. 1 ml of 
MeOH and 2 ml of CHCl3  was added and dounced  40 times. In this step, the internal 
standard for PC was added in order to correct for different extraction efficiencies 
between the samples. The suspension was transferred into an 8 ml glass vial. The used 
douncer was washed with 2 ml of CHCl3 and dounced 10 more times to take the 
residual amount of lipids on the surface of the douncer. The lysed cell suspension was 
spun down at the maximum speed for 8 minutes. The bottom organic phase was taken 
and blown with N2 to distill CHCl3. When no liquid was observed, the extracted lipids 
were resuspended in 200 ul of CHCl3.  
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The majority of detected PCs were the ones with C32:1, C34:1 and C34:2 of lipid 
class; a raw PC signal in each time-point was the sum of the raw intensities of the three 
members. Then, the raw PC signals were normalized by the used number of cells and 
the detected internal standard signal. 
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Chapter 4 
Conclusion 
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The metabolism in living organisms is highly adaptive in response to changes in 
nutrient availability because a quick adaptation to nutrient-limited environment is 
essential for cell survival. Pi is an essential nutrient and cells should be able to rectify a 
decrease in intracellular Pi concentration resulting from a Pi-limited condition. In 
Saccharomyces cerevisiae, the PHO pathway allows a coordinated cellular response 
and adaptation to changes in external Pi availability. The cellular response to Pi 
limitation and surplus conditions requires the ability of sensing Pi availability. Although 
the molecular mechanism of how the transcription of the PHO regulon responds to 
changes in Pi availability is well understood, little was known about how cells sense the 
Pi availability. 
 Given that signaling factors for the PHO pathway should be identified in order to 
understand the molecular mechanism by which cells sense Pi availability, I exploited 
two orthogonal experimental approaches; genetic screening is to identify protein 
components in the signaling network of the PHO pathway and metabolic profiling is to 
identify small molecules conveying information of Pi availability. From genetic screening, 
I found novel genes involved in upstream signaling of the PHO pathway and functional 
relationships among the identified genes. Metabolic profiling showed how the 
metabolome of Saccharomyces cerevisiae responded to changes in Pi availability. 
 These two experimental approaches addressed different aspects of the signaling 
of the PHO pathway, whereas the outcome of these two experiments converged to a 
particular metabolism: a connection between methyl cycle and purine metabolism 
(Figure 4.1). In addition to the purine metabolism genes ADK1 and ADO1 whose 
deletion lead to strong activation of the PHO pathway constitutively, my genetic 
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screening showed that another purine metabolism gene AAH1 also acts upstream of 
PHO81 and represses the PHO pathway in high Pi. This suggests that purine 
metabolism is relevant to sensing Pi availability. Moreover, SAH abundance was 
upregulated in Pi-limited conditions in my metabolic profiling and exogenous SAH in the 
growth medium could induce activation of the PHO pathway regardless of Pi availability. 
Given that SAH is connected to purine metabolism via adenosine, a byproduct of SAH 
hydrolysis and a substrate for Ado1, variations in SAH abundance in response to 
changes in Pi availability implicates that SAH is a potential activation signal of the PHO 
pathway. 
However, it still remains unclear that SAH is a Pi-dependent signaling factor for 
the PHO pathway. To address this issue, it will be necessary to confirm that the extent 
to which the PHO pathway is activated by an increase in SAH levels in the cells can be 
similar to the level induced by Pi starvation. In addition, measuring the PHO phenotype 
in the pho81 mutant in the presence of SAH will be crucial in order to determine that 
SAH activates the PHO pathway through the same route as Pi-limited conditions.   
I believe that my work will be useful resource for the future research on 
understanding the sensing mechanism of Pi availability. It will be interesting to explore 
more genetic interactions between the genes involved in upstream signaling of the PHO 
pathway shown in Supplementary table 2.1 and 2.2 in order to generate a more 
comprehensive map for the metabolic network relevant to the Pi sensing mechanism. 
And the further characterization of metabolic profiling data shown in Supplementary 
table 3.1 and 3.2 might be fruitful for continuing research on identifying small molecules 
like SAH that could be involved in sensing Pi availability. 
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Figure 4.1.  S-adenosyl-L-homocysteine (SAH) as a potential activation signal for the 
PHO pathway. Enzymes in blue were known as the ones involved in upstream signaling 
of the PHO pathway. SAH and Aah1 in red were identified in this study; Met, methionine; 
SAM, S-adenosyl-L-methionine; AMP, adenosine monophosphate; ADP, adenosine 
diphosphate; IMP, inosine monophosphate; GMP, guanosine monophosphate. 
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Appendix 1. Supplementary Tables 
 
Supplementary table 2.1.  List of constitutively induced mutants identified from the 
single mutant screening. The normalized log2 (YFP/RFP) ratio of the wild type in 50 uM 
Pi is 4.5. 
Gene averaged  log2 
(YFP/RFP) ratio 
normalized to WT in 
1mM Pi 
standard 
deviation 
p-value # of 
experiments 
PHO85 7.46 0.22 <1.0E-247 3 
PHO80 7.44 0.39 <1.0E-247 2 
ADK1 6.22 0.70 <1.0E-247 3 
ADO1 5.50 0.60 <1.0E-247 3 
REC8 4.47 3.96 2.7E-247 2 
AAH1 3.92 0.25 3.5E-191 3 
PHO90 3.83 0.81 1.1E-182 3 
SAM37 2.66 1.74 2.47E-90 3 
TUF1 2.54 0.20 9.7E-83 3 
HBS1 2.51 0.11 6.11E-55 2 
YOR200W 2.42 0.15 1.21E-75 3 
RPL2B 2.27 0.97 6.26E-67 3 
LDB7 1.97 0.95 5.81E-35 2 
SLM5 1.84 0.64 2.12E-45 3 
YER087W 1.81 0.64 3.56E-44 3 
PHO87 1.65 0.94 1.29E-37 3 
EAP1 1.37 0.02 1.14E-18 2 
SAC3 1.34 0.05 3.09E-26 3 
EOS1 1.23 0.05 9.96E-16 2 
OPI1 1.23 0.19 1.32E-22 3 
THP1 1.22 0.33 1.87E-22 3 
CTK3 1.10 0.10 2.85E-13 2 
PEX5 1.10 0.07 2.85E-13 2 
PPQ1 1.10 0.04 3.51E-13 2 
MFT1 1.09 0.04 9.54E-19 3 
HIS6 1.07 0.03 1.34E-12 2 
ECM30 1.04 0.03 4.04E-12 2 
RPA43 1.04 0.06 3.09E-17 3 
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Supplementary table 2.2.  List of weakly inducible mutants acting upstream of PHO80 
identified from the single mutant screening. The normalized log2 (YFP/RFP) ratio of the 
wild type in 1 mM Pi is -4.5 
Gene averaged  
log2 ratio 
normalized 
to WT in 50 
uM Pi 
standard 
deviation 
p-value Averaged log2 
ratio 
normalized 
ratio to the 
pho80 mutant 
number of 
measurements 
PHO81 -5.86 0.79 5.79E-31 -0.19 3 
PHO4 -5.23 0.34 4.23E-28 -8.19 3 
PHO2 -5.05 0.21 3.53E-24 -6.82 2 
YJL175W -4.87 1.33 1.66E-12 -0.29 2 
NSR1 -4.11 1.01 2.23E-18 -0.13 3 
TRM9 -4.10 1.33 1.81E-08 -0.55 3 
RPL36B -4.04 0.91 1.37E-15 -1.00 3 
YGL188C-A -3.86 1.14 1.08E-09 -0.80 2 
OPI11 -3.77 1.34 1.25E-12 -0.30 2 
DLT1 -3.48 1.68 1.64E-09 -0.37 3 
RPL20A -3.47 1.16 7.54E-08 -0.49 3 
LDB16 -3.42 1.50 1.44E-06 -0.55 2 
RSA1 -3.40 1.29 1.46E-05 -0.45 2 
SIM1 -3.37 1.65 7.49E-06 -0.24 3 
YBR196C-A -3.32 1.88 3.51E-10 -0.42 3 
RPL19B -3.30 2.83 3.10E-12 -0.34 3 
SHR3 -3.29 1.91 7.48E-10 -0.74 2 
EFG1 -3.22 1.17 2.80E-05 -0.29 3 
YOR309C -3.20 1.24 3.78E-12 -0.01 3 
SAK1 -3.03 2.09 2.74E-07 -0.59 3 
SPA2 -2.98 1.86 1.41E-10 -0.38 3 
SPT4 -2.97 0.94 4.24E-08 0.80 3 
YOR309C -2.94 1.59 3.78E-12 -0.08 3 
SSF1 -2.93 1.65 1.41E-05 -0.31 3 
SNF11 -2.90 1.83 1.91E-08 -0.65 3 
YPL225W -2.88 1.82 9.92E-04 -0.37 3 
APM3 -2.88 1.99 1.20E-11 -0.65 3 
YOR338W -2.85 1.77 3.31E-04 -0.27 3 
YPR197C -2.81 1.68 2.74E-07 -0.51 3 
YNL010W -2.78 2.03 2.07E-10 -0.32 3 
WHI2 -2.76 1.64 7.67E-06 -0.22 3 
CSM1 -2.73 1.83 2.61E-06 -0.30 3 
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EAF6 -2.73 1.86 5.38E-05 -0.52 3 
MTC6 -2.73 1.81 7.07E-09 -0.17 3 
STV1 -2.71 2.01 3.19E-09 -0.24 3 
YOL162W -2.68 1.60 6.57E-05 -0.46 3 
ATG27 -2.67 1.81 2.62E-05 -0.64 3 
RIT1 -2.67 1.72 8.92E-04 -0.35 3 
HSC82 -2.61 1.53 5.10E-04 -0.55 3 
RSA3 -2.59 1.75 1.10E-06 -0.18 2 
TMA23 -2.59 1.62 2.45E-13 -0.41 3 
RPL22A -2.58 1.68 2.90E-11 -0.92 3 
SCW10 -2.57 1.82 8.01E-05 -0.18 3 
YPR045C -2.56 1.44 1.28E-16 -0.15 3 
YNL320W -2.54 1.82 8.73E-04 -0.31 3 
RPL16A -2.54 1.71 3.33E-05 -0.36 2 
MNI1 -2.51 1.66 2.13E-05 -0.29 3 
AZF1 -2.50 1.81 3.83E-10 -0.22 3 
YJR011C -2.50 2.01 2.20E-06 0.28 3 
SKI3 -2.46 1.77 6.67E-07 -0.73 3 
YDR056C -2.46 1.77 5.68E-04 -0.32 3 
YPL077C -2.45 2.97 5.80E-04 -0.56 3 
MTC4 -2.41 1.84 1.90E-06 -0.22 3 
DAT1 -2.41 2.05 1.73E-07 -0.12 3 
THO2 -2.40 1.80 3.16E-06 -0.39 3 
STB2 -2.39 1.74 4.75E-11 -0.23 3 
FKH2 -2.39 1.80 1.20E-07 -0.20 3 
SPL2 -2.37 1.45 2.50E-04 0.00 3 
YPR050C -2.36 1.86 4.21E-05 -0.82 3 
YIL152W -2.35 1.89 1.12E-05 -0.24 3 
YKL075C -2.33 1.77 8.21E-11 -0.29 3 
RPS10A -2.32 0.97 2.74E-05 -0.65 3 
MTC2 -2.32 2.22 3.40E-06 -0.25 3 
RPL6B -2.32 1.61 1.45E-06 -0.66 3 
YNR025C -2.30 1.95 1.38E-05 -0.24 3 
BUD23 -2.30 1.62 3.33E-04 -0.20 2 
GAP1 -2.28 2.20 4.11E-04 -0.23 3 
RPS17A -2.27 1.08 4.68E-04 -0.56 3 
SGN1 -2.26 1.77 1.27E-04 -0.21 3 
APS3 -2.25 1.96 5.41E-10 -0.65 3 
NDJ1 -2.23 1.54 8.37E-05 -0.15 3 
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PAD1 -2.22 1.80 1.84E-04 -0.27 3 
MCT1 -2.22 0.93 3.77E-09 0.09 3 
DAL80 -2.22 2.02 4.99E-04 -0.19 3 
TMT1 -2.21 1.92 2.25E-06 -0.21 3 
RCE1 -2.20 2.13 1.02E-05 -0.37 3 
RHO2 -2.20 1.88 6.67E-07 -0.20 3 
TMA108 -2.20 1.83 3.22E-04 -0.13 2 
ARO1 -2.20 1.75 5.75E-05 -0.37 3 
SOL4 -2.20 1.95 7.51E-04 -0.33 3 
SLM6 -2.20 1.81 1.10E-09 -0.42 3 
MAG2 -2.18 1.81 1.20E-05 -0.30 3 
ARP8 -2.18 1.15 4.07E-11 -0.22 3 
YBR197C -2.13 2.11 9.31E-04 -0.30 3 
RGP1 -2.12 2.16 2.45E-05 -0.24 3 
BUL2 -2.12 2.17 3.07E-05 -0.18 3 
TPN1 -2.10 2.17 1.42E-04 -0.32 3 
HOM6 -2.10 2.14 8.36E-04 -0.76 3 
YML007C-A -2.05 2.14 1.82E-05 -0.23 3 
PIH1 -2.05 1.67 1.99E-09 -0.24 3 
BRX1 -2.04 1.94 6.32E-04 -0.31 3 
CEM1 -2.04 0.95 4.02E-08 -0.08 3 
FYV7 -2.03 1.84 1.09E-08 -0.57 3 
LAG1 -2.02 1.76 3.77E-04 -0.22 3 
YDL114W -1.97 1.80 2.97E-04 -0.42 3 
STM1 -1.97 2.05 1.35E-05 -0.36 3 
HUL5 -1.96 1.83 1.97E-04 -0.23 3 
YOR325W -1.96 2.15 3.28E-05 -0.41 3 
CSM2 -1.96 1.88 2.61E-04 -0.16 3 
ECM32 -1.94 1.95 7.19E-07 -0.21 3 
YEL007W -1.94 2.71 5.32E-04 -0.22 3 
VHS2 -1.94 1.75 1.72E-04 -0.23 2 
YOL097W-A -1.94 1.97 2.25E-06 -0.18 3 
SEC20 -1.93 1.96 1.70E-05 -0.19 3 
SWD1 -1.93 1.92 1.68E-07 -0.55 3 
CYK3 -1.93 2.10 5.00E-06 -0.84 3 
ARO9 -1.93 2.08 3.59E-05 -0.23 3 
RPS4B -1.93 2.21 4.69E-09 -0.34 3 
RAD16 -1.92 1.88 4.20E-04 -0.16 3 
BUD28 -1.91 1.73 2.33E-11 -0.89 3 
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YKL162C -1.91 1.75 5.88E-07 -0.16 3 
HIS2 -1.90 1.98 4.70E-05 -0.18 3 
MRT4 -1.90 1.41 2.42E-06 -0.58 3 
CGR1 -1.89 2.01 3.44E-05 -0.43 3 
YNL108C -1.89 1.88 1.14E-05 -0.28 3 
YLR428C -1.89 1.88 2.70E-08 -0.31 3 
ATG11 -1.88 1.70 4.85E-04 -0.30 2 
PXL1 -1.88 1.85 3.53E-04 -0.30 3 
ARO2 -1.87 1.90 1.61E-06 -0.30 2 
COG6 -1.87 2.00 1.92E-04 -0.29 3 
YJL120W -1.87 1.94 1.22E-06 -0.42 3 
GET3 -1.86 1.98 1.80E-06 -0.46 3 
FMP27 -1.85 1.74 4.68E-04 -0.40 3 
YGL261C -1.84 1.72 2.84E-04 -0.29 3 
RPL18B -1.84 1.84 2.24E-07 -0.38 3 
RPL9B -1.83 1.93 1.07E-06 -0.64 3 
ARO7 -1.83 1.78 2.34E-05 -0.28 3 
BUD7 -1.82 1.80 1.17E-05 -0.31 3 
YDR203W -1.81 2.70 3.45E-04 -0.38 3 
PCD1 -1.80 1.90 1.34E-06 -0.23 3 
SIP18 -1.79 1.80 4.40E-05 -0.37 3 
YMR242W-A -1.79 1.26 5.25E-06 -0.30 3 
YBR174C -1.79 2.11 4.68E-04 -0.63 3 
TRM10 -1.77 1.83 1.12E-10 -0.24 2 
RGD1 -1.77 1.76 3.69E-04 -0.36 3 
SEH1 -1.77 2.14 8.01E-05 -0.12 3 
MCH4 -1.77 1.89 1.19E-04 -0.37 3 
CSN12 -1.76 1.94 4.48E-04 -0.42 3 
YPR153W -1.76 2.15 1.97E-07 -0.26 3 
MRPL50 -1.76 2.01 1.48E-04 -0.27 3 
YPR114W -1.76 1.80 4.13E-06 -0.30 3 
FRE6 -1.75 1.79 8.92E-04 -0.24 3 
ITR2 -1.75 1.82 1.07E-04 -0.18 3 
CTK2 -1.75 1.53 1.65E-04 -0.34 3 
TIF6 -1.74 1.12 8.23E-06 -0.28 3 
YOR072W -1.73 1.80 3.61E-04 -0.33 3 
OXR1 -1.73 2.06 2.54E-06 -0.30 3 
SEO1 -1.72 1.84 5.32E-04 -0.35 3 
DDR2 -1.72 1.92 3.00E-05 -0.20 3 
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KSS1 -1.72 1.98 1.58E-04 -0.30 3 
SAL1 -1.70 1.94 9.31E-04 -0.24 3 
RPL41A -1.70 1.92 6.89E-04 -0.27 3 
PEA2 -1.70 2.12 8.18E-04 -0.15 3 
KTR7 -1.70 1.91 1.48E-05 -0.19 3 
ARO3 -1.69 1.62 4.20E-04 -0.27 3 
YAL037C-A -1.69 1.94 3.68E-05 -0.18 3 
HFD1 -1.69 1.85 3.31E-04 -0.50 3 
POR2 -1.69 1.86 8.01E-04 -0.24 3 
AST2 -1.67 1.96 3.02E-04 -0.14 2 
RPL16B -1.67 1.78 4.80E-07 -0.33 3 
YNL190W -1.67 1.81 3.76E-05 -0.12 3 
FBP26 -1.66 2.10 5.38E-05 -0.25 3 
YLR363W-A -1.65 2.10 1.27E-07 -0.19 3 
GAL83 -1.64 1.92 8.18E-04 -0.25 3 
YIL102C -1.64 1.88 2.31E-06 -0.15 3 
ECM30 -1.63 2.03 8.64E-05 -0.68 2 
YDL133W -1.63 2.11 5.88E-07 -0.30 3 
YPR123C -1.63 2.17 1.92E-07 -0.22 3 
YOL046C -1.62 2.04 4.40E-05 -0.30 3 
YKL199C -1.62 1.83 7.21E-05 -0.18 2 
YNL120C -1.62 2.66 9.78E-08 -0.19 3 
YHR199C -1.61 1.87 8.01E-04 -0.26 3 
RPL4A -1.61 1.75 8.29E-04 -0.27 2 
YNR004W -1.60 1.89 4.50E-05 -0.45 3 
PTM1 -1.59 2.08 7.84E-05 -0.31 3 
DMC1 -1.59 1.73 1.48E-06 -0.23 3 
YKL071W -1.59 1.61 4.12E-04 -0.24 2 
YMC1 -1.59 2.14 5.80E-04 -0.22 3 
YGR107W -1.59 1.66 5.38E-05 -0.25 3 
PDB1 -1.58 1.20 5.53E-04 -0.23 2 
SWD3 -1.57 2.07 9.15E-05 -0.65 3 
YML108W -1.57 2.06 9.92E-04 -0.53 3 
PNP1 -1.56 1.75 3.92E-04 -0.30 2 
RPL43B -1.56 2.03 1.24E-04 -0.46 3 
YPR172W -1.55 1.79 9.51E-04 -0.31 3 
YDR095C -1.55 2.12 1.82E-05 -0.33 3 
STE23 -1.55 1.96 3.84E-06 -0.26 3 
PSK2 -1.53 2.05 5.32E-04 -0.30 3 
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YGR035W-A -1.53 1.89 1.84E-04 -0.17 3 
HEF3 -1.52 1.75 1.24E-04 -0.17 3 
ARO8 -1.51 2.10 1.07E-05 -0.27 3 
MAL32 -1.51 2.03 3.93E-04 -0.19 3 
PEP5 -1.50 1.85 1.30E-04 -0.44 3 
YOR283W -1.50 1.84 1.19E-06 -0.19 3 
YER108C -1.48 1.88 2.24E-04 -0.14 3 
NMD4 -1.47 1.75 1.48E-04 -0.37 3 
YNL067W-B -1.46 2.03 1.14E-04 -0.97 3 
YKL077W -1.44 1.63 3.66E-06 -0.24 3 
EAR1 -1.43 1.91 3.32E-06 -0.37 3 
ARL1 -1.42 2.04 9.59E-04 -0.49 2 
TOF2 -1.41 1.84 1.12E-05 -0.22 3 
CRN1 -1.40 1.91 7.84E-05 -0.26 3 
NQM1 -1.39 1.74 1.35E-04 -0.23 2 
MET10 -1.38 1.79 1.56E-07 -0.41 3 
IPT1 -1.38 1.76 8.73E-04 -0.30 3 
YJL213W -1.38 1.98 8.75E-05 -0.27 3 
YHR033W -1.38 1.91 1.02E-05 -0.26 3 
FYV1 -1.36 1.56 9.35E-05 -0.98 3 
STI1 -1.35 2.01 7.84E-05 -0.33 3 
YKL063C -1.35 1.88 4.13E-08 -0.26 3 
EGD1 -1.35 1.92 2.39E-05 -0.52 3 
PDR16 -1.35 2.14 2.19E-04 -0.12 3 
PMD1 -1.35 1.81 1.88E-04 -0.23 3 
YJR107W -1.33 1.76 1.99E-05 -0.45 3 
YIL158W -1.32 1.89 2.14E-04 -0.17 3 
YMR272W-B -1.32 1.91 1.84E-04 -0.15 3 
BUD31 -1.31 0.80 7.50E-05 -0.34 3 
YER135C -1.30 1.91 1.55E-05 -0.24 3 
SNT309 -1.29 1.09 3.28E-04 -0.76 2 
SEY1 -1.29 1.61 1.00E-04 -0.23 2 
MNN9 -1.28 1.88 4.02E-07 -0.22 3 
RPC25 -1.28 0.90 8.78E-09 -0.78 3 
YGL140C -1.28 1.89 5.21E-04 -0.24 3 
YLL047W -1.27 1.70 3.10E-04 -0.21 3 
BRE1 -1.25 2.07 6.89E-04 -0.97 3 
YLR225C -1.25 1.78 2.14E-04 -0.21 2 
LRP1 -1.22 1.51 6.89E-04 -0.24 3 
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NAB6 -1.21 1.90 3.03E-04 -0.62 3 
YJR146W -1.20 1.87 1.22E-04 -0.38 3 
LYS14 -1.19 1.14 8.04E-06 -0.75 3 
THI12 -1.19 1.86 2.08E-05 -0.10 3 
PAI3 -1.18 1.88 5.80E-04 -0.26 3 
DBP3 -1.17 1.76 9.77E-05 -0.37 3 
TIF6 -1.16 1.44 8.23E-06 -0.38 3 
TKL1 -1.16 1.83 1.09E-04 -0.36 3 
YGR054W -1.15 2.01 2.19E-04 -0.17 3 
RPN14 -1.14 1.78 2.97E-04 -0.15 3 
RPL19A -1.14 1.67 3.20E-07 -0.83 3 
YGR160W -1.13 1.21 2.54E-07 -0.89 3 
YPS3 -1.12 1.93 5.10E-04 -0.30 3 
RAV2 -1.12 1.80 9.05E-06 -0.87 3 
MCK1 -1.11 1.80 2.39E-04 -0.62 3 
NCS2 -1.11 1.83 6.79E-08 -0.25 3 
ERG28 -1.11 1.86 2.78E-04 -0.25 3 
MMS2 -1.11 1.97 8.01E-04 -0.34 3 
YJL064W -1.10 1.97 5.75E-05 -0.34 3 
IMH1 -1.09 1.99 5.80E-04 -0.19 3 
RCK1 -1.09 1.84 1.13E-06 -0.22 3 
YGR122W -1.08 2.02 2.72E-04 -0.49 3 
YDL157C -1.07 1.89 8.18E-04 -0.23 3 
RRS1 -1.07 1.75 4.65E-06 -0.29 3 
KTI11 -1.07 1.46 1.60E-06 -0.22 3 
UBP13 -1.07 2.08 5.25E-06 -0.24 3 
MYO3 -1.04 1.77 1.84E-05 -0.21 2 
YMR209C -1.02 1.77 6.74E-04 -0.27 3 
CTK3 -1.02 1.87 8.73E-04 1.06 3 
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Supplementary table 2.3.  List of array strains used in the double mutant analysis. For 
constitutively induced mutants, normalized log2 ratios to the pho80 DAmP strain are not 
available. Some genes do not have normalized log2 ratios to the pho80 DAmP strain 
because I added them regardless of the screening data due to its interest. 
Gene normalized log2(YFP/RFP) 
to wild type in 50 uM Pi as a 
single mutant 
Averaged log2 ratio normalized 
ratio to the pho80 mutant 
THP1 -3.95 Constitutively induced mutants 
PHO80 2.51 Constitutively induced mutants 
YOR200W -2.21 Constitutively induced mutants 
PHO90 -2.44 Constitutively induced mutants 
SAC3 -3.47 Constitutively induced mutants 
ADK1 1.53 Constitutively induced mutants 
PHO87 -3.24 Constitutively induced mutants 
KCS1 0.57 Constitutively induced mutants 
EAP1 -3.07 Constitutively induced mutants 
AAH1 0.56 Constitutively induced mutants 
UGO1 -2.01 Constitutively induced mutants 
PHO85 2.55 Constitutively induced mutants 
RPL2B -3.18  
YER087W -3.26 Constitutively induced mutants 
MSN5 1.72  
ADO1 1.55 Constitutively induced mutants 
SEO1 -1.70 -0.35 
PEX22 -1.79 -0.43 
YPS3 -1.49 -0.30 
CHA4 -2.77 -0.54 
FYV7 -2.67 -0.57 
BUD28 -3.54 -0.89 
RPL22A -3.84 -0.92 
HSC82 -2.56 -0.55 
RPS17A -2.46 -0.56 
SWD1 -2.32 -0.55 
TRM9 -3.42 -0.55 
IRC25 -2.53 -0.81 
YMR010W -2.30 -0.44 
 85 
 
Supplementary table 2.3.  (Continued) 
SOK2 -1.81 -0.41 
PEP5 -1.86 -0.44 
SPA2 -3.00 -0.38 
FRE6 -1.74 -0.24 
YLL047W -1.53 -0.21 
RPL20A -4.25 -0.49 
RCE1 -2.32 -0.37 
RPS10A -2.18 -0.65 
BUD7 -1.87 -0.31 
PSK2 -1.95 -0.30 
YOL046C -2.31 -0.30 
RIT1 -1.91 -0.35 
TIR2 -2.16  
HST3 -2.03  
STI1 -1.83 -0.33 
SCW10 -1.52 -0.18 
YOR338W -1.77 -0.27 
THI12 -1.55 -0.10 
WHI2 -1.85 -0.22 
YNL320W -1.78 -0.31 
RPL18B -1.76 -0.38 
RIM21 -1.67 -0.33 
YOR072W -1.45 -0.33 
WHI5 -3.04  
YPL225W -1.71 -0.37 
YBR174C -2.09 -0.63 
SWD3 -2.09 -0.65 
DOA4 -4.10  
RPP2B -4.03  
IPT1 -1.24 -0.30 
SNF11 -3.26 -0.65 
OXR1 -2.49 -0.30 
YDR095C -2.28 -0.33 
RSA1 -4.50 -0.45 
YBR197C -1.39 -0.30 
PDB1 -1.34 -0.23 
YEL007W -1.17 -0.22 
ARO1 -2.50 -0.37 
GCN4 -2.45  
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RGP1 -2.10 -0.24 
MTC4 -2.61 -0.22 
RGD1 -0.96 -0.36 
SLM6 -3.27 -0.42 
MAK10 -1.93 -0.39 
YDR056C -1.56 -0.32 
NSR1 -4.73 -0.13 
YGR160W -2.09 -0.89 
PIH1 -3.05 -0.24 
YHR199C -1.38 -0.26 
RPS4B -2.43 -0.34 
LDB16 -3.69 -0.55 
SGF29 -1.07 -0.33 
SSF1 -2.54 -0.31 
ELP2 -1.62 -0.30 
LRP1 -1.90 -0.24 
CEM1 -2.06 -0.08 
UBA4 -2.66 -1.01 
SER3 -0.91 -0.11 
SPL2 -1.79 0.00 
ARO9 -2.19 -0.23 
MTC6 -2.99 -0.17 
LAG1 -2.24 -0.22 
YKL063C -1.39 -0.26 
STM1 -2.12 -0.36 
PCD1 -0.66 -0.23 
YKL071W -1.94 -0.24 
RUP1 -1.07 -0.31 
ARP8 -2.36 -0.22 
RPL26B -1.94  
YKL075C -1.92 -0.29 
YKL077W -1.04 -0.24 
YLR184W -2.00 -0.57 
NQM1 -1.45 -0.23 
SEY1 -1.06 -0.23 
YGR054W -1.67 -0.17 
MTC2 -2.64 -0.25 
PNP1 -1.17 -0.30 
APN1 -1.33 -0.15 
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Supplementary table 2.3.  (Continued) 
RPL11B -1.66  
RSA3 -2.27 -0.18 
YLR225C -1.09 -0.21 
MYO3 -1.64 -0.21 
YGR107W -1.02 -0.25 
MCT1 -2.77 0.09 
MRT4 -2.77 -0.58 
YGR122W -1.87 -0.49 
PTM1 -1.92 -0.31 
YKL162C -1.34 -0.16 
AZF1 -1.98 -0.22 
STE3 -1.42  
HNT3 -1.56  
YOR283W -1.62 -0.19 
NMD4 -1.35 -0.37 
ARO8 -2.39 -0.27 
ACO2 -1.86  
IMH1 -1.57 -0.19 
BUD19 -5.99  
ATG27 -2.49 -0.64 
FBP26 -1.90 -0.25 
YGL261C -1.20 -0.29 
YDR203W -2.59 -0.38 
RPS6A -2.24 -0.35 
BRO1 -4.23  
YLR345W -1.35 -0.33 
YPL077C -2.72 -0.56 
YPR172W -1.28 -0.31 
ATG13 -1.26 -0.16 
MLC2 -1.38 -0.14 
SKI3 -2.09 -0.73 
HPA2 -1.31 -0.16 
YPR197C -2.13 -0.51 
EGD1 -1.81 -0.52 
RIM8 -1.80 -0.59 
RPL19B -3.53 -0.34 
DBP3 -1.68 -0.37 
PAD1 -1.32 -0.27 
FMP37 -1.61  
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Supplementary table 2.3.  (Continued) 
MMS2 -1.60 -0.34 
YPR114W -1.33 -0.30 
UBP13 -1.63 -0.24 
RPS8A -1.41 -0.58 
PDR16 -2.07 -0.12 
YPR123C -2.15 -0.22 
PHO81 -5.99 -0.19 
RPN14 -1.17 -0.15 
YPR153W -2.13 -0.26 
YNL190W -1.48 -0.12 
YKL199C -1.19 -0.18 
YVH1 -0.96 -0.44 
RTT103 -2.86 0.91 
YDR290W -2.99 0.82 
BUD27 -3.02 -0.40 
HUA1 -1.11 -0.21 
TRM10 -1.27 -0.24 
ITR2 -1.10 -0.18 
NDJ1 -1.42 -0.15 
OPI11 -4.41 -0.30 
YPR045C -3.09 -0.15 
AIM22 -0.62 -0.21 
ATG11 -1.30 -0.30 
RPS7A -1.35 0.05 
ODC1 -0.68 -0.19 
MCH4 -1.24 -0.37 
MAK3 -2.67  
YMC1 -1.67 -0.22 
ARO7 -2.60 -0.28 
TKL1 -1.93 -0.36 
YML108W -1.87 -0.53 
DAT1 -3.00 -0.12 
SPO14 -2.38 -0.23 
ECM40 -3.76  
VIP1 -1.45 -0.19 
NAB6 -1.73 -0.62 
HTD2 -1.68 -0.94 
RIM13 -2.09 -0.60 
PHO84 -3.91 -0.44 
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Supplementary table 2.3.  (Continued) 
SNF6 -4.42 -0.74 
SNT309 -1.30 -0.76 
YOL162W -1.45 -0.46 
YJL120W -1.68 -0.42 
EAF6 -1.80 -0.52 
HFD1 -1.40 -0.50 
DLT1 -2.74 -0.37 
YJR146W -1.17 -0.38 
ICS3 -1.30 -0.36 
PXL1 -1.21 -0.30 
EAR1 -2.26 -0.37 
YMR209C -0.91 -0.27 
ELP6 -1.16 -0.30 
YJL064W -1.35 -0.34 
YJR107W -0.97 -0.45 
MAG2 -1.16 -0.30 
YLR428C -1.52 -0.31 
CRN1 -1.32 -0.26 
LYS14 -1.65  
ARO3 -0.95 -0.27 
ECM30 -1.49 -0.68 
HOM6 -1.74 -0.76 
YLR446W -1.06 -0.15 
RPL6B -2.59 -0.66 
FPR4 -1.67 -0.80 
HIT1 -4.28 -0.48 
SCS22 -1.24 -0.35 
APS2 -1.18 -0.29 
FMP27 -0.87 -0.40 
UNG1 -1.38 -0.27 
GET3 -1.62 -0.46 
YDL114W -1.39 -0.42 
CYK3 -2.37 -0.84 
YOR309C -3.24 -0.01 
PAI3 -1.09 -0.26 
SIP18 -1.18 -0.37 
YDL133W -2.16 -0.30 
YDL157C -0.84 -0.23 
CSM1 -1.88 -0.30 
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YGL214W -5.61  
APS3 -2.67 -0.65 
CSN12 -1.51 -0.42 
RPL43B -1.13 -0.46 
FYV1 -1.25 -0.98 
RPL41A -1.34 -0.27 
YJR011C -0.84 0.28 
YOR309C -1.75 -0.08 
YOR325W -2.20 -0.41 
YNL010W -3.22 -0.32 
POR2 -1.14 -0.24 
RAV2 -1.52 -0.87 
SIM1 -2.08 -0.24 
MET18 -1.03 -0.17 
YBR028C -1.15 -0.30 
RPL4A -1.29 -0.27 
CSM2 -1.30 -0.16 
RPL16A -1.14 -0.36 
VHS2 -1.50 -0.23 
KSS1 -1.61 -0.30 
TMA108 -1.92 -0.13 
SPT4 -2.82 0.80 
COG6 -1.27 -0.29 
YIL152W -1.23 -0.24 
SOL4 -1.07 -0.33 
ATO2 -1.06 -0.24 
YNR004W -0.76 -0.45 
SGN1 -1.45 -0.21 
YJL175W -4.23 -0.29 
RPL39 -3.89 -0.16 
YBR074W -1.00 -0.19 
MRPL50 -1.55 -0.27 
YNR025C -1.23 -0.24 
ACO2 -1.28 0.13 
YJL213W -1.13 -0.27 
THO2 -1.49 -0.39 
TOF2 -1.56 -0.22 
RPL9B -1.41 -0.64 
FKH2 -2.18 -0.20 
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DAL80 -1.84 -0.19 
GAP1 -1.40 -0.23 
YNL108C -1.42 -0.28 
SAL1 -0.94 -0.24 
RPL19A -2.14 -0.83 
MNI1 -1.34 -0.29 
NCS2 -1.28 -0.25 
YNL120C -1.42 -0.19 
APM3 -2.93 -0.65 
SNF5 -4.11  
BUD23 -1.94 -0.20 
VMA2 -1.99 -0.31 
TUP1 -2.42  
ADA2 -2.31  
HIS2 -1.28 -0.18 
GAL83 -2.02 -0.25 
MET10 -1.50 -0.41 
ARL1 -2.04 -0.49 
YPR050C -2.14 -0.82 
HIT1 -4.49 -0.24 
RAD16 -1.11 -0.16 
TMT1 -1.16 -0.21 
ECM32 -1.10 -0.21 
DMC1 -1.06 -0.23 
YGL140C -1.01 -0.24 
HUL5 -1.21 -0.23 
STE23 -1.17 -0.26 
RPC25 -1.35 -0.78 
ARO2 -1.64 -0.30 
STB2 -2.43 -0.23 
STV1 -1.98 -0.24 
RCK1 -1.08 -0.22 
MNN9 -0.45 -0.22 
YIL102C -0.90 -0.15 
YIL158W -0.76 -0.17 
DJP1 -0.95  
KTR7 -1.06 -0.19 
BRE1 -1.40 -0.97 
AST2 -1.03 -0.14 
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YER108C -1.00 -0.14 
LPD1 -1.49  
BUL2 -2.07 -0.18 
CTK3 -1.20 1.06 
ERG28 -0.52 -0.25 
YHR033W -1.07 -0.26 
BUD31 -1.40 -0.34 
MAL32 -0.13 -0.19 
SAK1 -2.77 -0.59 
PMD1 -0.68 -0.23 
YER135C -1.30 -0.24 
CTK2 -1.84 -0.34 
PEA2 -1.09 -0.15 
HEF3 -0.74 -0.17 
PDX3 -2.55  
YAL037C-A -1.12 -0.18 
KTI11 -1.70 -0.22 
SEH1 -1.24 -0.12 
YBR196C-A -3.34 -0.42 
TPN1 -1.59 -0.32 
MDJ1 -1.87  
YLR363W-A -1.12 -0.19 
YML007C-A -2.40 -0.23 
YMR242W-A -1.63 -0.30 
YGL188C-A 0.00 -0.80 
YGR035W-A -0.85 -0.17 
YMR272W-B -0.92 -0.15 
YNL067W-B -1.46 -0.97 
CGR1 -1.68 -0.43 
EFG1 -3.70 -0.29 
DDR2 -0.65 -0.20 
YOL097W-A -0.78 -0.18 
TMA23 -2.99 -0.41 
RHO2 -1.24 -0.20 
BRX1 -1.01 -0.31 
YPL038W-A -1.06 -0.20 
RPB4 -4.16  
YJR151W-A -3.24 -0.20 
RPL16B -1.67 -0.33 
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MCK1 -0.92 -0.62 
RPL36B -4.30 -1.00 
GPI11 -0.89 -0.46 
SEC20 -1.18 -0.19 
SPB4 -1.41  
SHR3 -3.55 -0.74 
TIM50 -1.85 -0.26 
RET1 -0.96 -0.29 
TIF6 -1.30 -0.38 
TIF6 -1.05 -0.28 
RRS1 -1.62 -0.29 
LYS14 -1.42 -0.75 
PTC4 -1.90 -0.53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
Supplementary table 2.4.  List of genes whose double mutant with the aah1 mutant is 
uninducible. Uninducible double mutants were chosen as the ones whose normalized 
log2 ratio to the wild type in 50 uM Pi is lower than -4. The reporter level of the wild type 
when the PHO pathway is repressed is -4.5. 
Gene normalized 
log2(YFP/RFP) 
to wild type in 
50 uM Pi as a 
single mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of the 
aah1 mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of the 
ado1 mutant 
VIP1 -1.66 -6.48 -4.47 
YJL175W -5.14 -5.91 -4.47 
RPL39 -3.98 -5.89 -2.93 
RPL36B -4.64 -5.71 -3.58 
PHO81 -5.75 -5.48 -5.16 
OPI11 -4.73 -5.45 -5.60 
BUD31 -1.06 -5.42 0.28 
TMA23 -3.91 -5.39 -4.55 
TRM9 -4.38 -5.34 -5.37 
YGL188C-A -1.55 -5.20 -2.39 
ACO2 -5.25 -5.17 -0.33 
IPT1 -1.59 -5.12 0.98 
RPS17A -1.17 -5.12 0.19 
YPR045C -2.85 -5.10 -5.79 
TUP1 -2.88 -5.03 -3.07 
PIH1 -2.31 -5.02 0.25 
RPP2B -3.52 -4.95 -0.12 
RSA1 -3.77 -4.89 -5.25 
RPS10A -1.69 -4.87 -0.79 
RPL19B -3.19 -4.85 1.14 
ARP8 -1.54 -4.83 -2.83 
EFG1 -4.17 -4.83 0.22 
BUD28 -1.99 -4.82 0.52 
MRT4 -0.68 -4.81 -0.13 
ADA2 -2.47 -4.80 -4.64 
NSR1 -3.97 -4.75 -1.19 
RPS6A -2.62 -4.73 0.74 
RPS8A 0.69 -4.71 0.05 
ARO2 -1.83 -4.70 1.00 
ELP6 -2.17 -4.65 1.12 
RPS4B -2.70 -4.61 -2.29 
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SSF1 -2.60 -4.56 0.12 
ECM40 -3.49 -4.44 -2.02 
ARO1 -2.61 -4.43 -0.22 
RPL20A -3.24 -4.42 0.35 
RPC25 -1.28 -4.39 -2.17 
RPL22A -3.27 -4.39 0.91 
TKL1 -0.79 -4.31 -3.99 
KTI11 -1.58 -4.31 -4.31 
RPL6B -2.79 -4.25 0.39 
WHI5 -3.79 -4.25 0.98 
RPS7A 0.58 -4.25 1.61 
LDB16 0.34 -4.24 -0.56 
YLR184W -1.08 -4.19 0.88 
BUD27 -1.82 -4.19 -0.74 
HSC82 -2.68 -4.18 1.12 
UBA4 -2.80 -4.18 1.18 
BUD23 -2.23 -4.16 1.43 
TIF6 -0.90 -4.13 -2.10 
SLM6 -2.60 -4.12 1.09 
SKI3 -2.72 -4.05 -0.85 
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Supplementary table 2.5.  List of genes whose double mutant with the ado1 mutant is 
uninducible. Uninducible double mutants were chosen as the ones whose normalized 
log2 ratio to wild type in 50 uM Pi is lower than -4. The reporter level of the wild type 
when the PHO pathway is repressed is -4.5. 
Gene normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
single mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of the 
aah1 mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of the 
ado1 mutant 
YPR045C -2.85 -5.10 -5.79 
OPI11 -4.73 -5.45 -5.60 
CTK2 -2.33 -3.30 -5.59 
TRM9 -4.38 -5.34 -5.37 
RSA1 -3.77 -4.89 -5.25 
SSM4 -0.22 -1.02 -5.18 
PHO81 -5.75 -5.48 -5.16 
ATG11 -2.61 -2.73 -5.01 
MMS2 -0.80 -1.06 -4.67 
ADA2 -2.47 -4.80 -4.64 
YEL007W -2.30 -0.20 -4.56 
TMA23 -3.91 -5.39 -4.55 
YML108W -1.85 -0.79 -4.53 
YJL175W -5.14 -5.91 -4.47 
RIM8 -1.07 1.53 -4.47 
VIP1 -1.66 -6.48 -4.47 
MAG2 -1.38 -1.79 -4.44 
KTI11 -1.58 -4.31 -4.31 
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Supplementary table 2.6. List of genes whose double mutant with the vip1 mutant is 
uninducible. Uninducible double mutants were chosen as the ones whose normalized 
log2 ratio to wild type in 50 uM Pi is lower than -4. The reporter level of the wild type 
when the PHO pathway is repressed is -4.5. 
Gene normalized 
log2(YFP/RFP) to 
wild type in 50 uM 
Pi as a single 
mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of the 
vip1 mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of the 
ipk1 mutant 
RPL39 -3.98 -6.86 -6.72 
BUD19 -0.15 -6.83 -6.69 
RPP2B -3.52 -6.56 -6.06 
YGL188C-A -1.55 -6.56 -5.37 
FYV7 -4.30 -6.40 -6.21 
YPR045C -2.85 -6.38 0.23 
RPL20A -3.24 -6.35 -6.02 
RPS7A 0.58 -6.29 -5.38 
YLR184W -1.08 -6.25 -5.52 
YMR242W-A -1.32 -6.23 -5.83 
NSR1 -3.97 -6.21 -5.60 
RPL36B -4.64 -6.20 -6.24 
RPL6B -2.79 -6.19 -5.13 
SLM6 -2.60 -6.18 -5.32 
RPL22A -3.27 -6.18 -5.32 
RPL11B -1.75 -6.17 -4.97 
TMA23 -3.91 -6.15 -5.22 
EFG1 -4.17 -6.15 -5.35 
TUP1 -2.88 -6.13 -6.20 
SSF1 -2.60 -6.09 -3.86 
BUD28 -1.99 -6.08 -5.29 
LRP1 -0.27 -6.08 -3.91 
MRT4 -0.68 -6.07 -3.85 
RPL16B -1.47 -6.04 -3.82 
DOA4 -3.88 -6.02 -5.19 
MET18 -1.89 -6.01 -5.17 
RRS1 -1.09 -5.99 -3.86 
RPS4B -2.70 -5.91 -3.60 
CTK2 -2.33 -5.88 -3.40 
YGR160W -1.06 -5.74 -5.28 
PHO81 -5.75 -5.73 -6.02 
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SPB4 -0.72 -5.73 -2.46 
BRX1 -3.66 -5.71 -2.72 
BUD23 -2.23 -5.66 -4.51 
RSA1 -3.77 -5.61 -4.94 
BUD27 -1.82 -5.61 -3.83 
SNF6 -5.14 -5.50 -2.21 
PDB1 -0.05 -5.48 -4.27 
WHI5 -3.79 -5.45 -3.48 
ARP8 -1.54 -5.42 -4.12 
MNI1 -2.44 -5.39 -2.14 
ELP6 -2.17 -5.37 -3.32 
RPL16A -2.98 -5.35 -2.42 
NPR2 -2.65 -5.27 -4.28 
MCT1 -1.94 -5.24 -5.13 
YJL175W -5.14 -5.10 -4.79 
RPS8A 0.69 -5.05 -1.80 
UBA4 -2.80 -4.91 -4.04 
RPL19A -1.73 -4.80 -2.12 
HTD2 -1.16 -4.78 -4.76 
UBP15 -0.65 -4.74 -2.09 
TIF6 -0.43 -4.72 -1.90 
SHR3 -3.28 -4.70 -1.23 
PIH1 -2.31 -4.69 -1.46 
HNT3 -0.17 -4.68 -2.37 
ELP2 -0.57 -4.66 -0.92 
RPC25 -1.28 -4.65 -2.62 
RSA3 -1.57 -4.65 -1.33 
CHA4 -2.73 -4.62 -2.24 
ARO1 -2.61 -4.59 -4.58 
CTK3 -1.20 -4.58 -1.13 
HST3 -2.66 -4.57 -2.98 
YKL075C -2.93 -4.57 -0.70 
GCN4 -1.78 -4.51 -4.90 
THP1 -2.63 -4.46 -2.68 
YNL120C -1.26 -4.46 -0.97 
PEP5 -1.55 -4.46 -0.33 
RPS6A -2.62 -4.43 -2.58 
FYV1 -1.80 -4.42 -4.12 
SEO1 -2.49 -4.40 -0.82 
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SPA2 -2.49 -4.34 -0.86 
APM3 -2.84 -4.34 -2.75 
DBP3 -1.69 -4.31 -1.29 
YDR290W -2.28 -4.17 -1.85 
RPL26B -1.94 -4.15 -0.16 
SNF5 -3.77 -4.14 -5.30 
YDR203W -1.54 -4.08 -1.69 
TCO89 -4.84 -4.06 -5.02 
RTT103 -2.75 -4.05 -1.32 
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Supplementary table 2.7.  List of genes whose double mutant with the ipk1 mutant is 
uninducible. Uninducible double mutants were chosen as the ones whose normalized 
log2 ratio to wild type in 50 uM Pi is lower than -4. The reporter level of the wild type 
when the PHO pathway is repressed is -4.5. 
Gene normalized 
log2(YFP/RFP) to 
wild type in 50 uM 
Pi as a single 
mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of the 
vip1 mutant 
normalized 
log2(YFP/RFP) to wild 
type in 50 uM Pi as a 
double mutant of the 
ipk1 mutant 
RPL39 -3.98 -6.86 -6.72 
BUD19 -0.15 -6.83 -6.69 
RPL36B -4.64 -6.20 -6.24 
FYV7 -4.30 -6.40 -6.21 
TUP1 -2.88 -6.13 -6.20 
RPP2B -3.52 -6.56 -6.06 
PHO81 -5.75 -5.73 -6.02 
RPL20A -3.24 -6.35 -6.02 
YMR242W-A -1.32 -6.23 -5.83 
NSR1 -3.97 -6.21 -5.60 
YLR184W -1.08 -6.25 -5.52 
RPS7A 0.58 -6.29 -5.38 
YGL188C-A -1.55 -6.56 -5.37 
EFG1 -4.17 -6.15 -5.35 
RPL22A -3.27 -6.18 -5.32 
SLM6 -2.60 -6.18 -5.32 
SNF5 -3.77 -4.14 -5.30 
BUD28 -1.99 -6.08 -5.29 
YGR160W -1.06 -5.74 -5.28 
TMA23 -3.91 -6.15 -5.22 
DOA4 -3.88 -6.02 -5.19 
MET18 -1.89 -6.01 -5.17 
RPL6B -2.79 -6.19 -5.13 
MCT1 -1.94 -5.24 -5.13 
TCO89 -4.84 -4.06 -5.02 
RPL11B -1.75 -6.17 -4.97 
CEM1 -0.85 -0.66 -4.95 
RSA1 -3.77 -5.61 -4.94 
GCN4 -1.78 -4.51 -4.90 
TRM9 -4.38 -1.92 -4.81 
YJL175W -5.14 -5.10 -4.79 
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HTD2 -1.16 -4.78 -4.76 
ARO1 -2.61 -4.59 -4.58 
BUD23 -2.23 -5.66 -4.51 
NPR2 -2.65 -5.27 -4.28 
PDB1 -0.05 -5.48 -4.27 
AIM22 -0.28 -1.03 -4.25 
FYV1 -1.80 -4.42 -4.12 
ARP8 -1.54 -5.42 -4.12 
UBA4 -2.80 -4.91 -4.04 
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Supplementary table 3.1. Relative abundance of metabolites to 10 mM Pi condition. 
Time course data obtained in no Pi were normalized to the values in 10 mM Pi. This 
table was used to generate Figure 3.1. 
 Time (minutes) 
Metabolites 0 2  5  10  15  30  60  90  
CTP 1.00 1.55 1.73 1.41 1.23 1.10 1.15 1.05 
phosphoenolpyruvate 1.00 1.28 1.00 1.27 1.44 1.00 1.53 1.44 
GMP 1.00 0.81 0.32 0.67 0.47 0.53 0.50 0.59 
CDP 1.00 0.59 0.66 0.64 0.67 0.84 0.68 0.60 
UDP-D-glucose 1.00 0.84 0.65 0.79 0.90 1.01 0.67 0.79 
glucose-6-phosphate 1.00 0.71 0.61 0.69 0.79 0.89 0.84 0.79 
ribulose-5-
phosphate/xylulose-5-
phosphate 
1.00 0.75 0.75 0.78 0.88 0.95 0.73 0.80 
guanine 1.00 0.33 0.63 0.48 0.68 0.69 0.70 0.88 
3-phosphoglycerate 1.00 0.52 0.55 0.62 1.37 1.22 0.96 1.34 
ribose-5-phosphate 1.00 0.83 0.75 1.06 1.11 1.08 0.88 0.80 
cytidine 1.00 0.84 0.87 0.58 1.09 0.99 0.47 0.57 
IMP 1.00 0.77 0.77 0.71 0.63 0.47 0.82 0.76 
fructose-1_6-bisphosphate 1.00 1.18 0.99 1.03 0.87 0.77 0.72 0.67 
sedoheptulose bisphosphate 1.00 0.99 0.82 1.04 0.87 0.76 0.90 0.64 
dihydroxyacetone phosphate 1.00 1.04 0.95 1.02 1.02 0.91 0.72 0.76 
UTP 1.00 0.96 0.98 1.14 0.95 0.85 0.73 0.86 
pyrophosphate 1.00 1.06 0.98 1.10 0.90 0.70 0.64 0.61 
N-carbamoyl-L-aspartate 1.00 0.74 0.71 0.77 0.59 0.38 0.51 0.49 
ADP 1.00 0.82 0.65 0.74 0.82 0.51 0.53 0.54 
NADP+ 1.00 1.00 0.87 0.88 0.80 0.53 0.43 0.40 
acetyl-CoA 1.00 1.04 0.99 0.89 0.62 0.37 0.43 0.43 
ATP 1.00 0.79 0.82 1.00 0.59 0.38 0.41 0.55 
dTTP 1.00 0.80 0.85 0.80 0.97 0.44 0.37 0.62 
FMN 1.00 0.87 0.78 0.70 0.73 0.53 0.49 0.49 
deoxyribose-phosphate 1.00 0.23 0.27 0.23 0.18 0.17 0.22 0.15 
glucono-delta-lactone 1.00 0.24 0.28 0.26 0.18 0.17 0.20 0.16 
GDP 1.00 1.33 1.09 0.97 0.70 0.40 0.41 0.45 
GTP 1.00 1.76 1.38 1.52 0.50 0.35 0.36 0.67 
glycerol-3-phosphate 1.00 1.12 1.06 0.95 0.73 0.81 0.69 0.66 
NAD+ 1.00 1.15 0.97 1.10 0.98 0.70 0.76 0.69 
NADH 1.00 0.97 1.14 1.00 0.88 0.57 0.53 0.49 
FAD 1.00 1.16 1.07 0.87 0.53 0.16 0.24 0.24 
dihydroorotate 1.00 0.65 0.58 0.49 0.45 0.13 0.30 0.28 
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Supplementary table 3.1.  (Continued) 
orotidine-5--phosphate 1.00 1.09 1.06 1.07 0.99 0.51 0.69 0.68 
glutathione 1.00 0.69 0.18 0.39 0.03 0.49 0.90 1.06 
S-methyl-5--thioadenosine 1.00 0.96 0.66 0.73 0.78 0.62 0.73 0.76 
AMP 1.00 0.51 0.31 0.44 0.44 0.41 0.45 0.39 
hydroxyisocaproic acid 1.00 0.18 0.15 0.21 0.22 0.23 0.48 0.51 
phenyllactic acid 1.00 0.14 0.16 0.19 0.22 0.27 0.51 0.61 
phenylpyruvate 1.00 0.19 0.17 0.20 0.24 0.36 0.66 0.77 
indole-3-carboxylic acid 1.00 0.03 0.05 0.03 0.07 0.08 0.17 0.19 
xanthurenic acid 1.00 0.02 0.02 0.03 0.04 0.06 0.12 0.20 
kynurenic acid 1.00 0.30 0.32 0.22 0.22 0.21 0.19 0.23 
orotate 1.00 0.24 0.27 0.26 0.20 0.14 0.28 0.33 
methylmalonic acid 1.00 0.55 0.44 0.42 0.40 0.38 0.47 0.60 
succinate 1.00 0.55 0.44 0.42 0.40 0.38 0.47 0.60 
dTDP 1.00 0.72 0.47 0.46 0.68 0.77 0.89 0.69 
pyruvate 1.00 0.91 0.87 0.93 0.90 0.98 1.00 0.98 
octulose-8-phosphate 1.00 0.54 0.32 0.49 0.82 0.97 0.72 0.66 
sedoheptulose-7-phosphate 1.00 0.56 0.61 0.72 0.88 0.99 0.87 0.83 
acetyllysine 1.00 0.75 0.78 0.82 1.15 1.36 1.09 1.15 
asparagine 1.00 0.86 0.77 0.64 0.72 1.25 1.06 1.05 
glutamine 1.00 0.96 0.83 0.83 0.93 1.20 0.99 1.10 
2-isopropylmalic acid 1.00 0.89 0.54 0.93 1.05 1.03 1.56 1.82 
serine 1.00 0.89 0.75 1.04 0.98 0.96 1.53 1.17 
homocysteine 1.00 0.65 0.63 0.80 1.02 1.39 1.51 1.04 
N-acetyl-glucosamine-1/6-
phosphate 
1.00 0.67 0.71 0.90 1.15 1.02 0.95 0.91 
CDP-ethanolamine 1.00 1.11 0.88 0.72 1.32 1.13 1.07 1.17 
UMP 1.00 0.66 0.59 0.60 0.62 0.77 0.88 0.77 
aspartate 1.00 0.90 0.74 0.78 0.92 1.18 0.96 1.01 
fumarate 1.00 0.73 0.60 0.54 0.52 0.81 0.99 1.55 
malate 1.00 0.74 0.61 0.51 0.47 0.76 0.94 1.55 
hypoxanthine 1.00 0.90 0.58 0.60 0.86 0.88 0.94 1.14 
imidazoleacetic acid 1.00 0.91 0.91 0.84 1.12 1.22 0.36 0.85 
sarcosine 1.00 1.14 0.54 1.07 1.12 1.44 0.55 0.70 
NADPH 1.00 0.94 1.23 1.37 1.68 1.34 1.23 1.12 
glutathione disulfide 1.00 1.30 2.11 1.94 2.70 1.86 1.58 1.74 
N-acetyl-L-alanine 1.00 2.44 1.87 2.13 2.04 2.55 1.63 2.23 
4-aminobutyrate 1.00 1.05 1.19 1.34 1.42 1.23 1.23 1.21 
glutamate 1.00 1.12 1.11 1.14 1.17 1.09 1.07 1.07 
aconitate 1.00 1.47 1.44 1.41 1.38 1.51 2.20 2.78 
citrate 1.00 1.41 1.53 1.48 1.43 1.79 2.49 3.20 
 104 
 
Supplementary table 3.1.  (Continued) 
S-adenosyl-L-homocysteine 1.00 19.2 17.1 15.2 16.4 17.7 14.0 16.6 
cystathionine 1.00 1.23 1.15 1.44 1.44 1.26 1.44 1.45 
gluconate 1.00 1.43 1.67 1.38 1.26 1.13 1.44 1.32 
N-acetyl-L-ornithine 1.00 2.49 3.22 2.65 1.89 1.62 1.96 1.51 
methionine sulfoxide 1.00 1.79 2.22 1.93 1.36 1.39 1.56 1.23 
indole 1.00 1.83 2.14 1.77 1.56 1.39 1.52 0.99 
trehalose 1.00 1.82 2.03 1.77 1.58 1.49 1.48 1.22 
hydroxyproline 1.00 2.91 3.02 2.56 2.56 2.22 2.02 1.85 
inosine 1.00 2.35 2.08 1.93 2.08 1.91 1.55 2.00 
guanosine 1.00 1.24 1.00 0.89 0.95 1.22 1.16 1.71 
ornithine 1.00 1.27 1.17 1.17 1.22 1.19 0.96 0.80 
trehalose-6-Phosphate 1.00 1.92 1.49 2.03 2.84 1.29 0.94 0.93 
glycerate 1.00 1.42 1.35 1.05 0.53 0.63 1.21 0.67 
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Supplementary table 3.2. Relative abundance of metabolites to no Pi condition. Time 
course data obtained in 10 mM Pi were normalized to the values in no Pi. This table was 
used to generate Figure 3.1. 
 Time (minutes) 
Metabolites 0  0.5  1.5  3  5  10  15  30  60  
CTP 1.00 1.73 1.70 1.55 2.00 1.76 1.72 1.65 1.77 
phosphoenolpyruvate 1.00 1.58 1.69 2.15 2.70 2.46 2.45 2.94 2.68 
GMP 1.00 2.00 1.59 1.66 1.54 1.95 2.31 1.86 1.86 
CDP 1.00 1.94 1.75 1.74 1.43 1.45 1.91 1.68 1.91 
UDP-D-glucose 1.00 1.38 1.34 1.27 1.29 1.20 1.63 1.29 1.31 
glucose-6-phosphate 1.00 1.15 1.26 1.32 1.45 1.60 1.33 1.46 1.45 
ribulose-5-
phosphate/xylulose-5-
phosphate 
1.00 1.10 1.05 1.03 1.26 1.37 1.57 1.52 1.60 
guanine 1.00 1.63 1.43 1.56 1.62 1.20 1.21 1.55 1.79 
3-phosphoglycerate 1.00 1.97 2.09 1.78 1.96 1.93 2.46 2.21 2.57 
ribose-5-phosphate 1.00 1.20 1.13 1.30 1.17 1.26 1.53 1.46 1.66 
cytidine 1.00 6.06 2.32 2.68 2.32 1.90 2.25 1.46 1.93 
IMP 1.00 2.24 1.57 2.38 3.13 2.13 2.65 3.18 3.30 
fructose-1_6-
bisphosphate 
1.00 1.26 1.39 1.54 1.52 1.53 1.47 1.53 1.64 
sedoheptulose 
bisphosphate 
1.00 1.22 1.20 1.50 1.51 1.51 1.54 1.46 1.41 
dihydroxyacetone 
phosphate 
1.00 1.55 1.47 1.29 1.56 1.22 1.61 1.56 1.72 
UTP 1.00 1.39 1.31 1.46 1.51 1.50 1.37 1.34 1.31 
pyrophosphate 1.00 42.8 42.5 45.1 44.2 43.0 38.4 37.1 30.7 
N-carbamoyl-L-aspartate 1.00 1.70 1.75 1.16 0.97 0.85 1.27 0.99 0.65 
ADP 1.00 1.26 1.19 1.14 1.20 1.24 1.21 1.09 1.02 
NADP+ 1.00 1.35 1.34 1.07 1.17 1.16 1.20 1.15 1.07 
acetyl-CoA 1.00 1.30 1.24 1.24 1.28 1.16 1.10 1.15 1.15 
ATP 1.00 1.32 1.32 1.38 1.54 1.53 1.39 1.44 1.34 
dTTP 1.00 1.23 1.30 1.26 1.38 1.58 1.35 1.46 1.39 
FMN 1.00 1.55 1.41 1.66 1.13 1.41 1.35 1.22 1.44 
deoxyribose-phosphate 1.00 3.19 3.23 3.87 3.86 3.79 2.89 3.58 2.60 
glucono-delta-lactone 1.00 3.34 3.38 3.78 3.73 3.41 3.15 3.21 2.34 
GDP 1.00 2.24 2.03 1.77 1.52 1.38 1.93 1.99 1.72 
GTP 1.00 1.59 1.45 1.54 1.88 1.64 1.56 1.59 1.37 
glycerol-3-phosphate 1.00 1.16 1.23 1.04 1.15 1.00 1.10 1.04 1.01 
NAD+ 1.00 0.96 0.97 0.97 0.93 0.98 0.94 0.96 0.94 
NADH 1.00 0.86 1.08 0.92 1.00 0.92 1.14 1.06 0.90 
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Supplementary table 3.2.  (Continued) 
FAD 1.00 0.93 1.04 1.11 0.91 0.94 0.74 0.80 0.59 
dihydroorotate 1.00 0.77 0.90 0.94 0.78 1.08 0.74 0.95 0.70 
orotidine-5--phosphate 1.00 1.00 0.98 1.00 0.86 0.94 0.89 1.22 1.52 
glutathione 1.00 1.04 0.98 0.97 1.00 0.99 0.89 0.93 0.79 
S-methyl-5--
thioadenosine 
1.00 1.01 0.77 0.82 0.92 0.98 0.84 0.91 1.00 
AMP 1.00 1.36 1.23 1.09 1.52 1.09 1.42 1.09 1.12 
hydroxyisocaproic acid 1.00 1.11 1.05 1.06 1.08 1.24 1.17 1.39 1.71 
phenyllactic acid 1.00 1.07 1.01 0.98 1.07 1.24 1.10 1.30 1.60 
phenylpyruvate 1.00 1.06 1.04 1.04 1.23 1.20 1.09 1.44 1.53 
indole-3-carboxylic acid 1.00 0.98 0.91 1.01 1.03 1.06 1.09 1.10 1.22 
xanthurenic acid 1.00 1.00 0.97 0.76 1.18 1.05 1.11 1.18 1.33 
kynurenic acid 1.00 0.83 0.82 0.73 0.83 1.01 0.81 0.98 1.32 
orotate 1.00 1.06 1.01 1.11 1.03 1.03 0.97 1.19 1.35 
methylmalonic acid 1.00 1.12 0.93 0.91 0.87 0.87 0.76 0.93 0.93 
succinate 1.00 1.12 0.93 0.91 0.87 0.87 0.76 0.93 0.93 
dTDP 1.00 1.33 1.00 0.97 1.16 1.21 1.51 1.24 1.26 
pyruvate 1.00 1.03 1.03 1.03 0.98 1.05 1.08 1.04 1.03 
octulose-8-phosphate 1.00 1.12 0.75 1.16 0.81 1.18 1.42 1.49 1.64 
sedoheptulose-7-
phosphate 
1.00 0.95 1.04 1.10 1.11 1.11 1.41 1.41 1.43 
acetyllysine 1.00 1.24 1.17 1.10 1.17 1.17 1.05 0.77 0.67 
asparagine 1.00 1.06 1.05 1.01 1.00 0.98 0.93 1.00 1.09 
glutamine 1.00 1.18 1.10 1.10 1.08 1.06 1.09 1.00 1.05 
2-isopropylmalic acid 1.00 1.17 1.17 1.10 1.20 1.25 1.26 1.30 1.37 
serine 1.00 1.19 1.12 1.00 1.09 0.99 1.00 0.98 1.04 
homocysteine 1.00 1.41 0.99 1.39 1.17 1.00 1.58 0.76 1.46 
N-acetyl-glucosamine-
1/6-phosphate 
1.00 0.90 0.85 0.96 1.07 0.99 0.96 0.87 1.18 
CDP-ethanolamine 1.00 1.05 1.35 0.80 0.37 0.66 0.73 0.79 1.48 
UMP 1.00 0.67 0.64 0.64 0.78 0.75 0.77 0.60 0.79 
aspartate 1.00 1.04 1.07 0.95 0.85 0.76 0.75 0.80 0.91 
fumarate 1.00 1.13 1.04 0.89 0.79 0.58 0.57 0.66 0.94 
malate 1.00 1.10 1.06 0.88 0.77 0.60 0.57 0.70 0.93 
hypoxanthine 1.00 1.13 1.03 0.85 0.86 0.85 0.78 0.91 1.31 
imidazoleacetic acid 1.00 1.07 0.92 0.92 1.13 0.59 0.76 0.81 0.71 
sarcosine 1.00 1.03 1.04 0.91 0.81 0.72 0.70 0.75 0.87 
NADPH 1.00 1.52 1.31 1.07 1.15 0.88 1.00 1.31 1.17 
glutathione disulfide 1.00 0.99 0.98 1.23 1.21 1.23 1.50 1.08 4.35 
N-acetyl-L-alanine 1.00 1.23 1.23 1.14 0.63 0.57 1.23 0.68 0.83 
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4-aminobutyrate 1.00 1.10 1.08 1.06 1.01 1.01 1.09 0.97 0.97 
glutamate 1.00 1.04 1.06 1.01 1.02 1.02 1.08 0.98 0.98 
aconitate 1.00 1.08 0.74 1.18 0.66 0.58 0.96 0.70 0.56 
citrate 1.00 1.12 1.21 1.15 1.12 1.03 0.90 0.68 0.47 
S-adenosyl-L-
homocysteine 
1.00 0.14 0.13 0.11 0.10 0.13 0.11 0.15 0.17 
cystathionine 1.00 0.86 0.90 0.77 0.83 0.76 0.91 0.71 0.89 
gluconate 1.00 0.84 0.92 0.89 0.93 0.85 0.74 0.81 0.66 
N-acetyl-L-ornithine 1.00 0.84 0.80 0.93 0.97 0.90 0.76 0.72 0.47 
methionine sulfoxide 1.00 0.84 0.82 0.91 0.87 0.87 0.74 0.74 0.61 
indole 1.00 0.83 0.82 0.78 0.88 0.85 0.63 0.68 0.51 
trehalose 1.00 0.88 0.92 0.75 0.85 0.84 0.63 0.68 0.60 
hydroxyproline 1.00 0.86 0.85 0.99 0.90 0.79 0.73 0.70 0.67 
inosine 1.00 1.05 1.09 0.90 0.79 0.75 0.60 0.64 0.69 
guanosine 1.00 0.80 0.74 0.54 0.59 0.53 0.44 0.46 0.53 
ornithine 1.00 0.86 0.75 0.74 0.74 0.74 0.72 0.67 0.70 
trehalose-6-Phosphate 1.00 0.48 0.43 0.46 0.55 0.61 0.73 0.80 0.78 
glycerate 1.00 0.71 0.69 0.73 0.80 0.80 0.66 0.70 0.62 
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